



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |   |
|---|-----------|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C12N 15/62, C07K 16/00, 19/00, 16/46,</b><br><b>C12N 15/85, A61K 39/395, G01N 33/577</b><br><b>// C07K 16/28, 16/40</b>  | <b>A1</b> | <b>(11) International Publication Number: WO 99/37791</b><br><br><b>(43) International Publication Date: 29 July 1999 (29.07.99)</b>  |
| <b>(21) International Application Number: PCT/EP99/00477</b><br><br><b>(22) International Filing Date: 25 January 1999 (25.01.99)</b><br><br><b>(30) Priority Data:</b><br>98200193.5      23 January 1998 (23.01.98)      EP<br><br><b>(71) Applicant (for all designated States except US):</b> VLAAMS<br>INTERUNIVERSITAIR INSTITUUT VOOR BIOTECH-<br>NOLOGIE [BE/BE]; Rijvisschestraat 120, B-9052 Zwij-<br>naarde (BE).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> SCHOONJANS, Rein-<br>hilde [BE/BE]; Kerkstraat 25, B-9850 Landegem (BE).<br>MERTENS, Nico [BE/BE]; Pauwstraat 58, B-9120 Melsele<br>(BE).<br><br><b>(74) Agent:</b> DE CLERCQ, Ann; Ann De Clercq & Co. B.V.B.A.,<br>Brandstraat 100, B-9830 Sint-Martens-Latem (NL).   |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR,<br>BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD,<br>GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,<br>KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,<br>MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,<br>SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU,<br>ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG,<br>ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,<br>TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI,<br>FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent<br>(BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE,<br>SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the</i><br><i>claims and to be republished in the event of the receipt of</i><br><i>amendments.</i> |
| <b>(54) Title: MULTIPURPOSE ANTIBODY DERIVATIVES</b><br><br><b>(57) Abstract</b><br><br><p>The present invention relates to a class of molecules specified as novel multipurpose antibody derivatives. This class of molecules is created by heterodimerization of two constituting components. Heterodimerization is obtained by the specific heterotypic interaction of a chosen VH-CH1 combination of immunoglobulin domains, with a chosen VL-CL combination of immunoglobulin domains. The VHCH1-VLCL interaction is proposed as a very efficient heterodimerization scaffold that could be efficiently produced. By choosing the appropriate VH and VL domains in the VHCH1 and VLCL context, a binding specificity can be constituted by the heterodimerization scaffold itself. One or both of the comprising VHCH1 and VLCL chains can thus be extended at either the N- or the C-terminus or both with other molecules, such as a toxin polypeptide, an enzyme, a hormone, a cytokine, a signaling molecule, or a single chain linked Fv fragment with the same or a different specificity.</p> |           |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

## MULTIPURPOSE ANTIBODY DERIVATIVES

**TECHNICAL FIELD**

The present invention relates to a class of molecules specified as novel multipurpose antibody derivatives. The invention further relates in particular to such antibody derivatives that have two or more  
5 antigen binding parts, derivatives that have at least two antigen binding parts, combined with at least one other function, such as a toxin, an enzyme, a cytokine, a hormone or a signalling molecule, and derivatives that have an antigen binding part, combined with at least two  
10 other functions.

**BACKGROUND OF THE INVENTION**

Due to their versatility, multipurpose antibody derivatives (mpAbs), such as bispecific antibodies  
15 (BsAb), immunotoxins and bifunctional antibodies are promising tools in the treatment of various (human) diseases. The first arm usually allows to specifically recognize a target cell (e.g. cancer cell) by means of an antigen binding function, while another determinant may  
20 be directed through an antigen binding function towards a second cell type (e.g. a cytotoxic T cell), or it may be a toxin, an enzyme (e.g. to locally cleave and activate a prodrug), a cytokine, a hormone or a signalling molecule.

The difficulty of producing functional BsAb in  
25 sufficient quantity and purity is still hampering the more general use of BsAb in clinical applications. When using the quadroma technology only 10% of the immunoglobulin pool is the correct, bispecific antibody. Therefore, time consuming and costly purification  
30 procedures are inevitable.

Chemical reassociation of antibody fragments suffers from loss of affinity by protein denaturation or unorthodox disulphide bond formation, as well as from the use of a chemical cross-linker, generating inactive,  
35 chemically modified structures.

Both these classical methods producing BsAb give rather low yields. Recombinant DNA methodology and

antibody engineering has greatly facilitated the production of antibody derivatives in heterologous expression systems. By genetic fusion of various antibody fragments to generate BsAb, the normal tetrameric antibody structure  $(H+L)_2$  is reduced. When the total Fc-portion is included, the self-association of the disulphide bridges in the hinge region reduces considerably the yield of heterodimeric BsAb. Hence purification away from bivalent, homodimeric by-products is still required. In order to improve the level of heterodimeric, bispecific product, a "Knobs-into-holes" principle has been developed to engineer the CH3 domains in the Fc-tail for preferential heterodimerization. The molecule proposed by Ridgway et al. (1996) comprises a complete Fc portion, which increases the molecular weight of the final protein beyond the optimal size for biodistribution. Furthermore, the Fc portion can interact with a multitude of Fc receptors present on various cells in the body, which can deviate the binding of this molecule to aspecific targets.

Small antibody-derivatives (such as sFv, bssFv, diabodies) have the advantage of easy penetration in solid tumors; moreover, partly because of the absence of high disulphide containing hinge regions, they can be produced in high amounts in heterologous expression systems. However, due to their small size, these molecules are generally cleared too rapidly from the circulation to allow efficient accumulation at the tumor site, while molecules of intermediate size have improved serum stability and retain satisfactory tissue penetration.

In order to achieve medium sized heterodimers, sFv have been linked by incorporating an additional peptide, leucine zippers, amphiphatic helices or streptavidin. These heterodimerization extensions, however, might be immunogenic.

Similar problems are encountered in the preparation of immunotoxins and antibody derivatives

having an enzymatic function. Monovalent single chain Fv fragments (sFv) or disulfide stabilized Fv fragments (dsFv) are predominantly used to construct toxin fusions. This results in weaker binding and poor internalization  
5 due to the monovalent binding, and rapid blood clearance due to the small molecule size.

#### **DISCLOSURE OF INVENTION**

In view of the above it is the object of the  
10 present invention to provide a class of molecules, specified as novel multipurpose antibody derivatives that can be efficiently prepared without many by-products, that have an intermediate size and that combine two or more antigenic binding sites, or one antigenic binding  
15 site with two or more other functions in one molecule.

This is achieved according to the invention by multipurpose antibody derivative, comprising the CL and VL domains of a first antibody with a desired first antigen binding specificity, the CH1 and VH domains of  
20 the said first antibody interacting with the CL and VL domains, and one or more other molecules having at least one further purpose coupled to one or more of the domains of the first antibody.

The invention is based on the potential of the  
25 specific VL-CL:VH-CH1 (referred to as "L:Fd") interaction to drive disulphide-stabilized heterodimerization of recombinant antibody-derived fusion proteins. The use of the L:Fd interaction which can be both natural or chimeric to drive heterodimerization has several  
30 advantages. First of all, their natural heterodimeric interaction circumvents the need for protein engineering to achieve complementarity. Furthermore, the interaction is very strong, in contrast to L:L homodimers which are only poorly formed or Fd:Fd homodimers which were never  
35 detected in eukaryotic expression systems. Also, in bacterial expression systems the Fd chain alone is aberrantly folded (Ward, 1992). Finally, a single,

natural disulphide bridge stabilizes the L:Fd heterodimer.

Each of the two domains of the light and heavy chain can be extended with another molecule (e.g. VL or 5 VH region, a sFv, a toxin, an enzyme such as a prodrug cleaving enzyme, a cytokine, a hormone, a signalling molecule, etc.).

Thus, the invention relates to a class of molecules specified herein as novel "multipurpose 10 antibody derivatives". This class of molecules is created by heterodimerization of two constituting components. Heterodimerization is obtained by the specific heterotypic interaction of a chosen CH1-VH combination of immunoglobulin domains, with a chosen CL-VL combination 15 of immunoglobulin domains. The VHCH1-VLCL interaction is proposed as a very efficient heterodimerization scaffold that could be efficiently produced. By choosing the appropriate VH and VL domains in the VHCH1 and VLCL context, a binding specificity can be constituted by the 20 heterodimerization scaffold itself. One or both of the comprising VHCH1 and VLCL chains can thus be extended at either the N- or the C-terminus or both with other molecules, such as a toxin, an enzyme, a cytokine, a hormone or a signalling molecule and derivatives that 25 have an antigen binding part for the purpose of combining these molecules with each other.

The construction of the Fab part of the antibody, fixed to relatively simple molecules such as bacterial alkaline phosphatase, or a truncated mutant 30 form of Pseudomonas exotoxin has been described before (Ducancel et al., 1993, Choe et al., 1994). However, unexpectedly it was found according to the invention that the L:Fd interaction is still able to drive the heterodimerization when one of the chains of the Fab is 35 fused to a complex molecule as a single-chain antibody fragment. Even more unexpectedly, it was found that also both chains of the Fab may be fused to other molecules,

without affecting the ability of the molecules to form preferentially heterodimers.

ScFv molecules consist of domains (VL and VH) of the same nature as can be found in the Fd and L chains, so wrongly formed non-functional derivatives could easily be expected. However, the findings as illustrated in the examples unexpectedly show that such molecules can be produced efficiently and is proven functional for all its components.

Surprisingly, this could be achieved with peptide linkers as short as a few amino acids. By excluding the hinge-region, dimerization of the Fab-scFv fusion is omitted. Homodimerization of some specificities might induce unwanted activating or inhibiting functions with effector cells. In order to avoid this, homodimerization through e.g. the hinge region can be avoided by excluding this region in the Fab-scFv molecule.

The other molecule(s) can be fused either to the C-terminus of the CH1, the N-terminus of the VH, the C-terminus of the CL and/or the N-terminus of the VL. In total, the invention offers 15 different variant types of combinations of other molecules with the L + Fd construct as a scaffold. The variant types are summarized in table 1. Each variant type can in turn be provided with various kinds of other molecules.

Table 1

| No. | other molecule on C-terminus CH <sub>1</sub> | other molecule on N-terminus VH | other molecule on C-terminus CL | other molecule on N-terminus VL |
|-----|--|---------------------------------|---------------------------------|---------------------------------|
| 1   | +  | -                               | -                               | -                               |
| 2   | -  | +                               | -                               | -                               |
| 3   | -  | -                               | +                               | -                               |
| 4   | -  | -                               | -                               | +                               |
| 5   | +  | +                               | -                               | -                               |
| 6   | -  | +                               | +                               | -                               |

|   |    |   |   |   |   |
|---|----|---|---|---|---|
| 5 | 7  | - | - | + | + |
|   | 8  | + | - | - | + |
|   | 9  | + | - | + | - |
|   | 10 | - | + | - | + |
|   | 11 | + | + | + | - |
|   | 12 | + | + | - | + |
|   | 13 | + | - | + | + |
|   | 14 | - | + | + | + |
|   | 15 | + | + | + | + |
|   |    |   |   |   |   |

10

The L:Fd acts as a "carrier" for the other molecule. In the case of an sFv as the other molecule, the total size of the sFv is increased due to the presence of the carrier. As a consequence it will not have the disadvantage of known sFv's or bssFv that are cleared too rapidly from the circulation. The L and Fd chains can if desired, constitute a binding specificity of their own. In this case, the L and Fd chains contribute a function of their own, apart from serving as a heterodimerization signal.

When a molecule of the invention combines two (different or equal) functions, it is called bifunctional. Similarly, when a molecule of the invention combines three or more than three different or equal functions, it is called trifunctional, respectively multifunctional. When a molecule of the invention is combining two, three or more antibody parts having a different specificity, it is called bi-, respectively tri- or multispecific. When a molecule of the invention is combining two, three or more antibody parts having the same specificity, it is called bi-, respectively, tri- or multivalent for the binding specificity.

In a first preferred embodiment, the invention provides for a novel, recombinant mpAB that is a bispecific, bifunctional antibody (BsAb) when the specificities are different or bivalent, bifunctional



antibody (BvAb) when the specificities are the same. These are based on the fusion of a Fab and a sFv, which is fused to the C-terminus of CH1 or CL. This molecule will have an intermediate size of about 80 kDa, satisfies  
5 the aforementioned criteria and incorporates preferential heterodimerization through its L:Fd domains.

According to a second preferred embodiment a similar antibody is provided which is also based on the fusion of a Fab and a sFv, but in this case the latter is  
10 fused to the N-terminus of VH or the N-terminus of VL. In a third preferred embodiment, the invention provides for a novel, recombinant bispecific, trifunctional or bivalent, trifunctional mpAB that is an immunotoxin based on the fusion of a BsAb or a BvAb according to the first  
15 embodiment and a toxin, which is fused to the C-terminus of the heavy chain of the Fab that does not carry the sFv.

According to a fourth preferred embodiment, the invention provides for a novel, recombinant bispecific,  
20 trifunctional or bivalent, trifunctional mpAB that is called a catalytic antibody (cAb) based on the fusion of a BsAb or a BvAb and an enzyme, which is fused to the C-terminus of the heavy chain of the Fab that does not carry the sFv.

25 According to a fifth preferred embodiment, the invention provides for a novel, recombinant bispecific, trifunctional or bivalent, trifunctional mpAB that is combined with a hormone, a cytokine or a signalling function by fusing of a molecule with said activity to an  
30 BsAb or a BvAb according to the first embodiment.

According to a sixth preferred embodiment both the C-terminus of CH1 and the C-terminus of CL are fused to a sFv, resulting in a molecule with three antigen binding parts. This molecule is trifunctional, and can be  
35 trivalent monospecific, bivalent bispecific or monovalent trispecific.

Thus, this invention offers inter alia the possibility to create bivalent trifunctional immunotoxins

(i.e. molecules that are intended for two purposes, namely bivalent antigen binding and toxicity) or trispecific (i.e. three antigen specificities), antibodies. In the latter case not only the CH1, but also  
5 the CL is extended with an sFv.

The other molecule can be linked to the L or Fd antibody part(s) directly or via a linker. The presence of a linker of at least 1, preferably more than 3 amino acids can be used to avoid steric hindrance between two  
10 or more antigen binding sites and between antigen binding site(s) and the active center of the other molecule. Linkers other than amino acid chains may also be used.

According to one specifically preferred embodiment of the invention various anti murine CD3 $\epsilon$ -  
15 single-chain fragments (sFv) were fused to the C-terminus of CH1 of an Fd fragment specific for human placental alkaline phosphatase (hPLAP). This Fab-sFv bispecific antibody derivative (of the general formula Fab-linker-sFv, wherein the linker is e.g. EPSG but can be variable  
20 in sequence and length) can be used to link cytotoxic cells to tumor cells.

The fusion product was further improved for reaching far apart antigens by providing a sufficiently long spacer sequence (of the general formula Fab-linker-  
25 sFv, wherein the linker is e.g. EPSGP(G<sub>4</sub>S)<sub>3</sub>M but can be variable in sequence and length). After eukaryotic secretion, specific heterodimerization between the corresponding anti-hPLAP light chain and the Fd fragment occurred, where the latter carried a functional sFv. Upon  
30 expression in mammalian cells more than 90% of the immunoglobulin material in the medium was the specific heterodimer, with only minor contamination of light chain derived homodimers and monomers, which did not show hPLAP binding capacity. Homodimers from the heavy chain derived  
35 VH-CH1 fused to the anti CD3 $\epsilon$  sFv were never observed.

The Fab-sFv fusion protein between the anti murine CD3 $\epsilon$  sFv and the anti-hPLAP-Fab here described is an example for the efficient production of specific,

disulphide stabilized heterodimers which can be used for making bispecific antibodies. The invention is not limited to this particular example. Other antigen binding specificities can be used and for the other purpose or  
5 function there is also a variety of options. The invention lies in principle in the finding that the L:Fd interaction is highly specific and can be used as a heterodimeric scaffold to construct a new type of mpAb. The VL and CL domains in the L chain, as well as the Vh  
10 and CH1 domains in the Fd chain do not necessarily have to be derived from the same antibody.

The derivatives of the invention can be used in the treatment of tumors, in the treatment of various infected cells, in the treatment of autoimmune diseases  
15 or thrombosis. Moreover the derivatives of the invention can be used to direct a virus towards immunological effector cells, to induce or resolve blood clotting, to eliminate specific cell types in vitro or in vivo, to establish or improve transfections, or in diagnosis.

20 The invention further relates to DNA constructs encoding the heavy chain domains of an antibody derivative of the invention, comprising suitable transcription and translation regulatory sequences operably linked to sequences encoding the VH and CH1  
25 domains of the first antibody and optionally a coding sequence for the other molecule operably linked thereto.

In such a DNA construct the coding sequence for the other molecule may consist of DNA sequences encoding the VL and VH domains of a second antibody, which DNA  
30 sequences are operably linked to each other in either one of the sequences 5'-VL2-VH2-3' or 5'-VH2-VL2-3'.

In the DNA construct a DNA sequence encoding a linker sequence may be incorporated between one or more of the VH, CH1, VL2 and/or VH2 coding sequences and/or  
35 the coding sequence for the other molecule. The linker helps in avoiding steric hindrance between the various domains.

A particularly preferred DNA construct, designated as pCA2C11sFvE6Hf, is obtainable from E.coli DH5 $\alpha$  cells deposited on October 15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the  
5 deposit accession no. LMBP3715. Another preferred DNA construct is designated as pCAE6HfGS2C11sFv (also identified as pCAE6H2sc2C11H) and obtainable from E.coli MC1061 cells deposited on October 15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the  
10 deposit accession no. LMBP3716.

Furthermore the invention relates to DNA construct encoding the light chain domains of an antibody derivative of the invention, comprising suitable transcription and translation regulatory sequences  
15 operably linked to sequences encoding the VL and CL domains of the first antibody and optionally a coding sequence for the other molecule operably linked thereto. The coding sequence for the other molecule may consist of DNA sequences encoding the VL and VH domains of a second  
20 antibody, which DNA sequences are operably linked to each other in either one of the sequences 5'-VL2-VH2-3' or 5'-VH2-VL2-3'.

Also in this DNA construct a linker sequence can be incorporated between one or more of the VL, CL,  
25 VL2 and/or VH2 coding sequences and/or the coding sequence for the other molecule.

According to a further aspect the invention relates to a set of DNA constructs for producing multipurpose antibody derivatives of the invention,  
30 comprising any one of the constructs described above together with a construct encoding at least the light domains VL and CL of the first antibody or together with a construct encoding at least the heavy domains VH and CH of the first antibody, depending on whether the other  
35 construct encodes the heavy or light domains of the first antibody.

In a first embodiment the set consists of vector pCAE6H2sc2C11H and vector pCAG6SE6L. In an

alternative embodiment the set consists of vector  
pCA2C11sFvE6Hf and vector pCAG6SE6L. Those sets can be  
used for producing multipurpose antibody derivatives of  
the invention in heterologous expression host cells. The  
5 invention also relates to a method for producing  
multipurpose antibody derivatives, comprising expression  
of such a set in heterologous expression host cells. The  
host cells may be E.coli cells, other bacterial cells,  
such as Bacillus spp., Lactobacillus spp. or Lactococcus  
10 spp.; actinomycetes; yeasts; filamentous fungi; mammalian  
cells; such as COS-1 cells, HEK cells, insect cells,  
transgenic animals or plants.

Another aspect of the invention relates to a  
medical preparation, comprising multipurpose antibody  
15 derivatives.

A further aspect of the invention relates to  
the use of multipurpose antibody derivatives in  
diagnosis.

According to a final aspect the invention  
20 relates to the use of multipurpose antibody derivatives  
for the preparation of a medicament for the treatment of  
cancer, infections, parasites, autoimmune diseases,  
thrombosis.

The term "purpose" is used herein to indicate a  
25 certain activity or other function, preferably antigen  
binding specificity, toxicity, signalling or enzymatic  
activity.

The term "derivative" is used herein to refer  
to molecules other than the classic antibodies consisting  
30 of two light chains and two heavy chains, which heavy  
chains in turn comprise multiple constant domains. The  
derivatives comprise at least one VL domain, one CL  
domain, one VH domain and one CH domain.

Derivatives of the present invention can thus  
35 be prepared by genetic engineering using methods well  
known in the art. In the examples that follow, it is  
described how by genetic engineering, a new type of  
bispecific antibody with potential use in immunotherapy

by redirected cellular cytotoxicity was designed. The design of the antibody was based on the very effective and selective heterodimerization of the two antibody-chains, L and Fd. Both the Fd and the L chain can be  
5 extended with new determinants, herein called "other molecules" (peptides, domains), either at their N-terminus or C-terminus or both. As an example the molecule Fab (L + Fd) is described extended either at the N-terminus or at the C-terminus of the Fd fragment with a  
10 single chain antibody fragment (sFv). The latter, Fab-(G<sub>4</sub>S)<sub>3</sub>-sFv, was characterized in detail. (G<sub>4</sub>S)<sub>3</sub> is short for EPSGPGGGGSGGGGSGGGGSM. The bispecific species was the predominant product in a heterologous expression system. It had an intermediate molecular weight which is  
15 beneficial for serum stability, biodistribution and solid tissue penetration.

The following examples provide the teaching starting from which variants can be prepared. The examples are therefore in no way intended to be limiting  
20 the invention. In the examples "VH", "CH1", "CL" and "VL" are used for domains derived from the first antibody. "VH2" and "VL2" are used for domains derived from the second antibody. "VH3" and "VL3" are used for domains derived from the third antibody.

25

#### **BRIEF DESCRIPTION OF THE FIGURES**

In the examples reference is made to the following figures:

Figure 1: Diagram of the pSV51 (Huylebroeck et al., 1988), pCAGGS (Niwa et al., 1991) and pCDNA3.1zeo<sup>-</sup> (Invitrogen, Carlsbad, CA, USA) expression vector inserts used for transfection. E6=parental anti hPLAP antibody, 2C11=derived from the 145-2C11 parental anti CD3 antibody, B1=parental anti BCL1 antibody, 3D5=parental  
30 anti (His)<sub>5,6</sub> antibody, VL and CL=variable domain and constant domain of the light chain, VH and CH1=variable and first constant domain of the heavy chain, Bla=Escherichia coli  $\beta$ -lactamase, mIL2=mouse interleukin 2.

All light chain domains of E6 are in black, all heavy chain domains of E6 in white. 2C11scFv and 3D5scFv domains are hatched. BlscFv domains, Bla and mIL2 are in grey.

5           **Figure 2:** Heterodimerization of CL- and CH1 containing molecules in eukaryotic cells can be dependent on the pairing of appropriate VL and VH domains.

**Figure 3:** Expression of C-terminal Fab-scFv fusion proteins.

10           **Figure 4:** C-terminal Fab-scFv fusion proteins are functional as bispecific antibodies.

**Figure 5:** Chimeric L:Fd chains molecules can be used to heterodimerize Fab-scFv bispecific antibodies.

**Figure 6:** Expression, functionality  
15 purification and serum stability of bispecific Fab-scFv molecules with Fab chains.

**Figure 7:** Fd:L can efficiently heterodimerize two different scFv molecules.

**Figure 8:** Functionality of the trispecific  
20 antibody derivatives.

**Figure 9:** Expression of multivalent antibody derivatives.

**Figure 10:** Expression of multifunctional antibody derivatives.

25

## **EXAMPLES**

### **MATERIALS AND METHODS**

#### **Preparation of constructs**

#### **30 Bacterial strains and cell lines**

**E. coli** MC1061 (F<sup>-</sup>araD139 Δ(ara-leu)7696 galE15 galK16 Δ(lac)X74 rpsL (Str<sup>r</sup>) hsdR2(r<sub>k</sub><sup>-</sup>m<sub>k</sub><sup>+</sup>) mcrA mcrB1) and DH5α (endA1 hsdR17 (r<sub>k</sub><sup>-</sup>m<sub>k</sub><sup>+</sup>) supE44 thi-1 recA1 gyrA (Nal<sup>r</sup>) relA1 Δ(lacIZYA-argF)U169 deoR (Φ80dlacΔ(lacZ)M15)) were  
35 used for transformations and DNA isolations. The bacteria were grown in LB medium, supplemented with 100 μg/ml triacillin. The COS-1 cell line, derived from monkey CV-1 kidney cells, was used for eukaryotic expression.

HEK293T, a human embryonic kidney cell line transfected with SV40 large T-antigen (SV40T tsA1609) (DuBridge et al., 1987) was used for eukaryotic expression. TE<sub>2</sub> cells are murine, CD3 positive "T helper"-1 cells (Grooten et al., 1989), and were cultured in RPMI1640 medium (GibcoBRL life technologies, Paisly, UK) supplemented with 30 U/ml recombinant murine IL2, 0.06 mM BME, 10% FCS, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin and 0.4 mM sodium pyruvate. Mouse fibrosarcoma derived MO<sub>4</sub> cells were cultured in REGA-3 medium (GibcoBRL) supplemented with 10% FCS, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin and 0.4 mM sodium pyruvate. MO<sub>4</sub>I<sub>4</sub> (hPLAP<sup>+</sup>) cells are MO<sub>4</sub> cells transfected with the hPLAP gene (Smans et al., 1995; Hendrix et al., 1991). BCL1<sup>visc</sup> cells (gift from Dr. Thielemans) were cultured as TE<sub>2</sub> cells but with IL2.

#### Plasmids and gene assembly

Restriction enzymes were purchased from GibcoBRL life technologies (Paisly, UK), Vent DNA polymerase was from New England Biolabs (Beverly, MA, USA), T4 DNA ligase, Klenow enzyme and T4 DNA polymerase were from Boehringer Mannheim (Mannheim, Germany). All enzymes were used as recommended by the manufacturers. All primers for PCR amplification were purchased from GibcoBRL. DNA amplification was performed in a Biometra heat block using a predenaturing step of 10 min at 94°C, followed by 30 cycles, containing a denaturing step (94°C), an annealing step (55°C), and an extension step (72°C), each for 30 sec.

All expression modules are schematically represented in figure 1.

The cloning of the light chain (L) and the truncated heavy chain fragment (Fd) of the parental murine anti hPLAP mAb E6 (IgG2b, κ) in the vectors pSV51E6L (LMBP2142) and pSV51E6Hf1 (LMBP2143), respectively, was described previously (De Sutter et al., 1992a).



pSVE6sFvE6CL

A single-chain fragment of the anti hPLAP VH and VL was cloned in the vector pSV51E6sFv (LMBP3609, unpublished and provided by S. Dincq and K. De Sutter, VIB-RUG, Gent) and was used to replace VL in pSV51E6L (De Sutter *et al.*, 1992a) by BanII-AvaI fragment exchange. The resulting vector pSVE6sFvE6CL encodes E6scFv-CL.

pSV2C11sFvE6CH1E

The vector pc/DNA/AMP containing the anti CD3 scFv in the VL-L-VH configuration was kindly provided by Dr. D. Segal (Bethesda, MD, USA). Via site directed mutagenesis with the linker 5' CCGTCTCCTCAGAGCTCCAAAAACCC 3' a SacI site (underlined) was created immediately after the scFv. In the vector pSV51-2C11sFvMG2fEtag, the BamHI-SacI flanked 2C11scFv was fused in front of the E-tagged mouse IgG2b Fc-portion. In this vector we replaced the mouse heavy chain fragment with PCR amplified CH1 domain, digested with SacI and NotI. The CH1 domain was amplified from the vector pSV51E6Hf1 with the forward primer 5' CACTGCCGAGCTCCAAAAAC 3' (SacI site underlined) and the reversed primer 5' TCATGTGCGGGCCGCGCTCTA 3' (NotI site underlined). As a result the vector pSV2C11sFvE6CH1 was coding for 2C11scFv-CH1. Finally, the CH1 domain was exchanged with the E-tagged CH1 domain from the vector pCAsc2C11E6Hf (see below) by a BalI-SalI restriction digest. This resulted in the vector pSV2C11sFvE6CH1E.

pSVBlaE6CH1E

The pSV71 vector containing the BlaL1Hi insert (De Sutter *et al.*, 1992b) was the source of the EcoRV-SacI insert that replaced the EcoRV-SacI excised 2C11scFv from pSV2C11sFvE6CH1E. In this way pSVBlaE6CH1E was made, coding for Bla-CH1. The 14 amino acids of linker 1 (VNHKPSNTKVDKRV = last amino acids of mouse IgG2b CH1 and part upper hinge) and the amino acids of the SacI site (EL) are linking both subunits, adding up to a 16 amino acid linker connecting CH1 and Bla.

pCAGGSE6L

The eukaryotic expression vector pCAGGS was a gift from Dr. J. Miyazaki (University of Tokyo, Japan) (Niwa et al., 1991) and contains an ampicillin resistance gene, the strong constitutive  $\beta$ -actin/ $\beta$ -globin hybrid promoter and part of exon 3, 3' UTR and polyA signal of the rabbit  $\beta$ -globin gene. pCAGGSE6L (LMBP3547-IDA97-33, unpublished and kindly provided by Dr. J. Demolder, VIB-RUG, Gent) was made by ligating the XbaI fragment (filled-in with Klenow DNA polymerase) from pSV51E6L containing the E6L-sequence to a MscI-opened vector fragment of pCAGGS.

pCA2C11sFvE6Hf

2C11sFv-Fd gene assembly was achieved in the vector pCA2C11sFvE6Hf (LMBP3715-IDA97-34) containing the following fragments (clockwise): MscI-opened vector pCAGGS (Niwa et al., 1991); SspI-BamHI fragment from pSV51 (Huylebroeck et al., 1988), 2C11sFv encoding fragment from pCDNA/AMP/2C11 (Jost et al., 1994) cut in the BamHI- and in a introduced Ecl136II-site; Fd encoding fragment from pSV23SE6Hm (Dr. W. Lammerant, RUG, Ph.D. thesis 1994) flanked by KpnI (T4 blunted) and the 2 nucleotides of the BanII-site; NotI (Klenow blunted)-BsmI (T4-blunted) fragment from pCANTAB5E (Pharmacia LBK Biotechnology, Uppsala, Sweden) encoding the E-tag; SalI (blunted)-XbaI (blunted) fragment of pSV51.

pSVE6H1sc2C11M

The Fd-H1-2C11sFv fusion gene in pSVE6H1sc2C11M was made by ligating the NdeI (Klenow blunted)-AvaI fragment of pCDNA/AMP/2C11 (Jost et al., 1994) in the ApaI (T4 blunted)-SalI vector fragment of pSV51E6H (De Sutter et al., 1992a), encoding the E6 heavy chain that was truncated after the third amino acid of the hinge region (Fd, no cysteins included). The connecting sequence (encoding the additional EPSG) between E6Fd and 2C11sFv was confirmed by DNA sequence

analysis. This anti CD3 scFv was in the VL-linker-VH configuration and carried an c-myc tag.

#### pCAE6H1sc2C11H

5           The Fd-H1-2C11scFv fusion gene in pCAE6H1sc2C11H was also made by ligating a PCR-amplified 2C11scFv-encoding fragment to the C-terminus of E6Fd. The PCR fragment encodes the the 2C11scFv in the VH-VL configuration with a (His)<sub>6</sub> tail and it was amplified from  
10 pQE-bssFvB1-2C11 (De Jonge *et al.*, 1995, kindly provided by Dr. K. Thielemans, VUB, Belgium) with the forward primer 5' GGGCCATGGAGGTCAAGCTGGTGGAGTC 3' and the reverse primer 5' ATAGGATCCTTATCCGGACCTTTTATTTCCAGCTTGGTGCCAG 3' (BamHI site underlined). This PCR fragment was cut in the  
15 BamHI site and kinated. Subsequently we cloned in the MscI-BglIII opened pCAGGS vector (Niwa *et al.*, 1991), the HindIII (blunted)-ApaI fragment of pSV23sE6Hm (Dr. W. Lammerant, RUG, Ph.D. thesis 1994), encoding the Fd fragment, and the PCR fragment, encoding 2C11scFv.

20

#### pCAE6H2sc2C11H

Fd-H2-2C11scFv gene assembly was achieved in the vector pCAE6H2sc2C11H (LMBP3716-IDA97-35), containing the following fragments: MscI-BstXI opened pCAGGS vector  
25 (Niwa *et al.*, 1991); HindIII(blunted)-ApaI fragment of pSV23sE6Hm (Dr. W. Lammerant, RUG, Ph.D. thesis 1994) encoding the Fd fragment; PCR fragment amplified from pQE-bssFvB1-2C11 (De Jonge *et al.*, 1995) with the forward primer 5' GCTGAAAGGGCCCGGTGGAGG 3' (ApaI site,  
30 underlined) and with the reverse primer 5' GGTCACAGGGCACTGGCCTCACTCTAGAG 3' (BstXI site, underlined). This PCR fragment encodes a (G<sub>4</sub>S)<sub>3</sub>.linker, a anti murine CD3ε scFv in the VH-VL configuration and a (His)<sub>6</sub>-tail.

35

#### pCAE6L2sc2C11

The E6L-L2-2C11scFv gene assembly was performed in the vector pCAE6L2sc2C11, containing the following

fragments: HpaI-BstXI opened pCAGGSE6L vector; PCR fragment (coding for CL) amplified from pCAGGSE6L with the forward primer: 5' CAGTGAGCAGTTAACATCTGG 3' (HpaI site, underlined) and with the reversed primer: 5'

5 CCTTTGGGGCCCACACTCATTCC 3' (ApaI site, underlined); PCR fragment amplified from pQE-bssFvB1-2C11 (De Jonge et al., 1995) with the forward primer:

5' GCTGAAAGGGCCCGGTGGAGG 3' (ApaI site, underlined) and with the reversed primer:

10 5' GTGCCAGGGCACTGGTTAAGATCTGGATCC 3' (BstXI site, underlined). This PCR fragment encodes a (G<sub>4</sub>S)<sub>3</sub>-linker, a anti murine CD3ε scFv in the VH-linker-VL configuration and a stop codon.

#### 15 pCAB1E6H2sc2C11H

The chimeric Fd chain with variable sequences derived from the anti BCL1 mAb B1 and the constant sequence derived from the anti hPLAP mAb E6: VH(B1)-CH1(E6) coupled to the anti murine CD3 2C11scFv was

20 assembled in the pCAB1E6H2sc2C11H vector as follows: the B1VH domain, together with its natural signal sequence, was PCR amplified from the vector pEFBOS-bssFvB1-2C11 (kindly provided by Dr. K. Thielemans, VUB, Belgium) with the forward primer 5' CCTCACCTCGAGTGATCAGCACTG 3' (XhoI site underlined) and the reverse primer 5' CCACCTGAGGAGACAGTGACC 3' (Bsu36I site underlined).

Subsequently the E6CH1 in pCAE6H2sc2C11H was flanked with a Bsu36I site by PCR amplification using the forward primer 5' CTGCCTCCTCAGGCAAAACAACACCC 3' (Bsu36I site underlined), the reverse primer 5' GGACCCAGTGCATGCCATAGCC 3' (SphI site underlined). These two PCR fragment were ligated in the XhoI-SphI open vector pCAE6H2sc2C11H.

#### pCAB1E6L

35 The VL(B1)-CL(E6) chimeric light chain was assembled by substituting the DNA sequence of the mature VL(E6) gene in pCAGGSE6L with that of the mature VL(B1). The resulting vector pCAB1E6L contains the following

fragments (clockwise): XbaI-Tsp45I fragment of pCAGGSE6L encoding the E6H signal sequence; the VL(B1) sequence amplified from pEFBOS-bssFvB1-2C11 with the forward primer 5' GGATGTGACATTGTGATGACC 3' (Tsp45I site underlined) and the reverse primer 5' GATCCTTTGAGCTCCAGC 3' (SacI site underlined), the CL(E6) sequence amplified from pCAGGSE6L with the forward primer 5' GTTGGAGCTCAAACGGGCTG 3' (SacI site underlined) and the reverse primer 5' GGAGCTGGTGGTGGCGTCTCAGGACC 3' (BsmBI site underlined); XbaI-BsmBI opened vector pCAGGSE6L.

#### pCDE6L4scB1 and pCDE6L4E6

The construction strategy of this plasmid involves the construction of pCAGGSE6Lm2. This construct was made by PCR amplification of the E6L gene from pCAGGSE6L (Dr. J. Demolder, VIB-RUG) with the forward primer 5' ATACCGCTCGAGACACAGACATGAGTGTGCCCCACTC 3' (XhoI site underlined) and the reverse primer 5' CGCGGATCCTTACCCGGGGACGTCACACTCATTCCTGTTGAAGCTCTTGAC 3' (BamHI site underlined) with the purpose to create additional cloning sites at the N- and C- terminus of the E6L gene.

For the construction of pCDE6L4scB1, the B1scFv was PCR amplified from the vector pFE12-B1 (kindly provided by Dr. K. Thielemans) with the forward primer 5' TCCCCCGGGGAAGTGAAGCTGGTGGAGTCTG 3' (SmaI site underlined) and the reverse primer: 5' ATAGGATCCTTATCCGGATTTCAGCTCCAGCTTGGTCCCAGC 3' (BamHI site underlined). This PCR fragment was digested with BamHI and phosphorylated. Subsequently the PCR fragment was ligated with the SmaI-BsaI vector fragment of pCAGGS and the BsaI-BamHI fragment of pCDNA3.1zeo<sup>-</sup> (Invitrogen). In this way a hybrid vector frame was created, designated as pCD, who's promoter region is derived from the pCAGGS vector and who's 3' untranslated region, zeocin resistance gene and multi-cloning site are derived from the vector pCDNA3.1zeo<sup>-</sup>.

pcDE6L4scE6 was constructed in exactly the same way, only the E6scFv gene was amplified from pSV51E6sFv (S. Dincq, VIB-RUG) with the forward primer: 5' TCCCCCGGGCAGGTTTCAGCTGCAGCAGTCTGGAG 3' and the reverse primer 5' ATAGGATCCTTATCCGGACCGTTTTATTTCAGCTTGGTCC 3'.

#### pcDE6L5scB1 and pcDE6L5scE6

These two constructs are immediately derived from the pcDE6L4scB1 and pcDE6L4scE6 vectors by inserting two complementary adaptor oligonucleotides in the AatI and XmaI sites between the E6L and the scFv genes. The oligonucleotides 5' CGACGGTGGTTCTAGAGGTGATGGGC 3' and 5' CCGGGCCCATCACCTCTAGAACCACCGTCGACGT 3' were allowed to hybridize, resulting in AatI and XmaI sticky ends and the adaptor was then cloned.

#### pcDE6L6scE6

This vector contains the following fragments (clockwise): XhoI-Bsp120I(blunted) fragment of pCAE6L2sc2C11 encoding E6L, AatII(blunt)-XhoI vector fragment of pcDE6L4scE6 encoding E6scFv.

#### pcDE6H6scE6

This vector contains the following fragments (clockwise): XhoI-Bsp120I (blunted) fragment of pCAE6H2sc2C11H encoding E6Fd, AatII(blunt)-XhoI fragment of pcDE6L4scE6 encoding E6scFv.

#### pcDE6L7scE6

This vector contains the following fragments (clockwise): XhoI-Bsp120I(blunted) fragment of pCAE6L2sc2C11 encoding E6L, two complementary oligonucleotides: 5' GGCCTCAACCACAACCTCAGCCGCAACCTCAACCTGGGC 3' and 5' CCGGGCCCAGGTTGAGGTTGCGGCTGAGGTTGTGGTTGA 3' that form Bsp120I and XmaI sticky ends, XmaI-XhoI vector fragment of pCAE6L6scE6.

pCDE6H7scE6

This vector contains the following fragments (clockwise): XhoI-Bsp120I fragment of pCDE6H6scE6 encoding E6Fd, two complementary oligonucleotides

- 5' GGCCTCAACCACAACCTCAGCCGCAACCTCAACCTGGGC 3' and  
 5' CCGGGCCCAGGTTGAGGTTGCGGCTGAGGTTGTGGTTGA 3' that form Bsp120I and XmaI sticky ends, XmaI-XhoI vector fragment of pCDE6L6scE6.

10 Constructs with 3D5scFv

The plasmid pAK100His2 (Knappick *et al.*, 1994), coding for the anti His scFv 3D5, was a kind gift of Dr. A. Plückthun (Zurich, Switzerland). The 3D5 scFv was amplified from pAK100His2 with the forward primer 5'

- 15 TCC~~CCCCGGG~~GACATTTTGATGACCCAAACTCCAC 3' (SmaI site underlined) and the reverse primer  
 5' ATAGGATCCTTAT~~CCGG~~ATTCGGCCCCGAGGCCGCAGAGACAG 3' (BspEI site underlined) and was fused to an E-tag coding sequence

- 20 (~~TCCGGAGCGCCGGT~~GCCGTATCCAGATCCGCTGGAACACGTGGCGCCTAAGGATC  
C, BspEI site and BamHI site underlined) in the pCD vector. The SmaI-SpeI fragment of this construct, encoding the E-tagged scFv 3D5 (abbreviated 3D5E), was used to assemble the following vectors:

- 25 pCDE6L4sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCDE6L4scB1

pCDE6L5sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCDE6L5scB1

pCDE6L6sc3D5E: Fragment 3D5E ligated to SpeI-SmaI

- 30 fragment of pCDE6L6scE6

pCDE6L7sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCDE6L7scE6

pCAE6L8sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCAE6Lm2

35

pCDE6L61mIL2

The E6L-mIL2 fusiongene was assembled by ligating the following fragments: XhoI-Bsp120I(blunt)

fragment of pCDE6L6scE6 encoding E6L, NdeI(blunt)-BamHI fragment of pLT10mIL2ST (Mertens *et al.*, 1995) encoding mIL2, and the XhoI-BamHI vector fragment of pCDE6L4sc3D5E.

5

pCDE6H61mIL2 and pCDE6H62mIL2

These vectors were assembled by ligating the following fragments: the XhoI-BamHI vector fragment of pCDE6L4sc3D5E, NdeI(blunt)-BamHI fragment of pLT10mIL2ST encoding mIL2 and a fragment of pCDE6H6scE6 encoding E6Fd, excised with XhoI-Bsp120I(blunt) for the H61 linker or cut with XhoI-XmaI for the H62 linker.

#### Plasmids for electroporation of SP2/0 cells

15 In the vector pCAB1E6L a zeocin resistance gene was inserted by replacing the BglIII-ScaI fragment of the pCAGGS vector with the BamHI-ScaI fragment of the pCDNA3.1zeo<sup>+</sup> vector (Invitrogen, Carlsbad, CA, USA). This new plasmid was named pCDB1E6Lzeo. Analogously a  
20 neomycine resistance gene was inserted in pCAB1E6H2sc2C11H by replacing the HindIII-ScaI fragment of the vector, with the HindIII-ScaI fragment of pCDNA3 (Invitrogen). This resulted in the vector pCDB1E6H2sc2C11Hneo.

25

#### **Transfection protocols**

Unless otherwise stated, all cultures were grown at 37°C with 5% CO<sub>2</sub> in Dulbecco minimal essential medium (DMEM, GibcoBRL life technologies, Paisly, UK)  
30 supplemented with 10% FCS, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin and 0.4 mM sodium pyruvate.

Transfection of COS-1 cells was performed as described in De Sutter *et al.* (1992). HEK293T (DuBridge  
35 *et al.*, 1987) cells were transfected by a Ca<sub>3</sub>(PO<sub>4</sub>)<sub>2</sub> method. 20h before transfection, subconfluent monolayers were trypsinized and reseeded at 2.25 x 10<sup>6</sup> cells / 75 cm<sup>2</sup>. 2 h before transfection 35 ml of fresh medium was added to



the cells. 14  $\mu$ g of sterile, ethanol precipitated DNA of each expression plasmid (purified on a Qiagen DNA purification column, Qiagen Inc., CA, USA) was redissolved in 1400  $\mu$ l 0.1 x TE buffer (1x TE: 10 mM Tris.HCl, 1 mM EDTA) pH 7.5, and mixed with 350  $\mu$ l 1.25 mM  $\text{CaCl}_2$ , 125 mM Hepes-NaOH, pH 7.5. This DNA-solution was slowly added to 1 x Hepes/ 2x BS (25 mM Hepes-NaOH pH 7.5; 16 g/l NaCl; 0.74 g/l KCl; 0.50 g/l  $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ ; 2 g/l Dextrose) while continuously shaking. After 1 minute additional shaking, the mixture was transferred to the medium covering the cells and incubated for 24 h at 37°C.

Subsequently, the mixture was removed from the cells and replaced by 35 ml DMEM supplemented with 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin, 0.4 mM sodium pyruvate, 5 mg/l bovine insulin, 5 mg/l transferrin and 5  $\mu$ g/l selenium. Medium was harvested after 24 or 72 h. Dead cells were removed from the medium by centrifugation at 1100 rpm for 5 min and the culture supernatant was concentrated over a membrane with a cut-off value of 10 kDa (Centricon-10<sup>®</sup> microconcentrator or a Centriprep-10<sup>®</sup> concentrator membrane, Amicon Inc., Beverly, MA, USA).

In order to change the buffer, the concentrated supernatant containing the bispecific antibody (35 ml to 2.5 ml on Centriprep-10) was diluted with 12.5 ml PBS(A) (= 171.1 mM NaCl, 3.4 mM KCl, 10 mM  $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ , 1.8 mM  $\text{KH}_2\text{PO}_4$ ) supplemented with 0.05 % bovine serum albumin (BSA) and 0.02 % azide, and concentrated again to 1.5 ml. Cells were lysed with 10% NP-40 (Nonidet P40), containing 10% aprotinin, 100 mM Tris.HCl, pH 8.0, and 10 mM EDTA.

#### HEK293T production of Fab-scFv BsAb

For HEK293T production of 1 mg bispecific B1Fab-scFv we seeded  $4 \times 10^7$  HEK293T cells in 10 culture flasks of 175 cm<sup>2</sup> and after 24 hours these cells were cotransfected with pCAB1E6L and pCAB1E6H2sc2C11H (140  $\mu$ g of each plasmid) using the standard  $\text{Ca}_3(\text{PO}_4)_2$  transfection method described. After 24 h the precipitate

was removed and the cells were allowed to grow in ITS supplemented medium. Every 48h, this medium was harvested and changed. This was repeated six times resulting in 1.75l medium that was filtered with a bottle top filter 5 (Nalgene).

#### Electroporation of Fab-scFv in SP2/0 cells

SP2/0-Ag14 cells, growing in log phase were harvested and resuspended at  $4 \times 10^6$  cells in 400 $\mu$ l growing medium (RPMI 1640, supplemented with 10% foetal calf serum, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin,  $5 \times 10^{-5}$   $\beta$ ME and 0.4 mM sodium pyruvate) and kept on ice. 15  $\mu$ g of each plasmid (pCDB1E6Lzeo and pCDB1E6H2sc2C11Hneo) was linearized by a 15 ScaI digest. The plasmids were ligated and the mixture was purified by a phenol-ether extraction, precipitated and resuspended in 20  $\mu$ l bidest. 1 minute before electroporation the DNA was mixed with  $4 \times 10^6$  cells in the electroporation cuvet (gap 0.4 cm) and kept on ice. 20 The electric pulse (900  $\mu$ F, 250 V) was generated by an EASYJECT Plus (Molecular Technologies inc., St Louis, MO, USA). Immediately after the pulse 1 ml of fresh medium was added to the cells and they were transferred to a 12 cm<sup>2</sup> culture plate. 48 h later the electroporated cells 25 were incubated with growing medium containing 0.6 mg/ml zeocin) and 0.6 mg/ml neomycin. After 30 days the surviving cells were transferred to larger culture flasks or diluted for subcloning, and the culture medium was analysed.

30

#### Characterization of expressed proteins

Concentrated medium fractions of transfected cells corresponding to 500  $\mu$ l supernatant, were diluted with 3 x non-reducing sample buffer (New England Biolabs, 35 Beverly, MA, USA), boiled for 5 min and subjected to 10 % SDS-PAGE (Laemmli, 1970). After gel electrophoresis, the proteins were transferred to a nitrocellulose membrane (BA85; 0.45 $\mu$ m; Schleicher & Schuell, Dassel, Germany)

using the semi-dry Multiphor II NovaBlot system (1 mA/cm<sup>2</sup>; 1.5 h; Pharmacia LBK Biotechnology, Uppsala, Sweden).

Subsequent detection of the proteins on the blot was performed as follows: after blocking the  
5 membrane in blocking solution (5% (w/v) reconstituted, dried skimmed milk in 50 mM Tris.HCl, pH 8.0, 80 mM NaCl, 3 mM NaN<sub>3</sub> and 0.2% NP-40), the blots were incubated for 1.5 h with the anti murine  $\gamma$  and  $\kappa$  detection sera each 1:1000 diluted in blocking solution (goat anti murine Ig  
10 serum and goat anti murine  $\kappa$  serum, both 1 mg/ml, Sera-Lab LTD, Crawley Down, U.K.). Subsequently the blots were washed three times with blocking solution and incubated for another 1.5 h with rabbit anti goat IgG serum conjugated to alkaline phosphatase (Sigma Immuno  
15 Chemicals, St-Louis, MO, USA) 1:7500 diluted in blocking solution. Finally, the membrane was washed extensively with substrate buffer (0.1 M Tris.HCl, pH 9.5, 0.1 M NaCl and 50 mM MgCl<sub>2</sub>) and then developed by incubation with nitro-blue-tetrazolium and 5-bromo-4-chloro-3-indolyl  
20 phosphate (Promega, Leiden, The Netherlands) in substrate buffer. This staining reaction was stopped by rinsing the blot with water.

The antigen-binding capacity after blotting was analyzed by incubation of the blocked filter with soluble  
25 hPLAP (Sigma Chemical Co., St-Louis, MO, USA, final concentration 0.1 U/ml in blocking solution), followed by the specific enzymatic staining reaction as described above.

For densitometric measurements, the blots  
30 containing immunoreactive signals were scanned with a desktop scanner and analyzed by the whole Band Analyses software (Bio Image, Ann Arbor, MI, USA). The integrated intensity was calculated for each lane in terms of percentage.

35 Anti E-tag immunodetection was achieved with an murine anti E-tag antibody (1:1000, Pharmacia LBK Biotechnology, Uppsala, Sweden). Anti His-tag

immunodetection was achieved with anti-His tag antibody (Qiagen Inc, Valencia, CA, USA ).

Both incubation steps were followed by a anti-murine IgG1 serum conjugated to alkaline phosphatase (Pharmingen, San Diego, CA, USA). Subsequent enzymatic staining was performed as described above.

The purified and biotinylated BCL1 IgM molecule was a kind gift of Dr. K; Thielemans (VUB, Belgium). It was used in a final concentration of 1 µg/ml to incubate immunoblots containing the B1Fab-scFv or B1scFv molecule. Subsequently the blot was treated with streptavidin conjugated to alkaline phosphatase (Life Technologies, Paisley, UK) and stained with the same enzymatic reaction as described above.

15

#### **IMAC purification of bispecific Fab-scFv**

##### **Column preparation:**

For large scale purification a Hi-Trap chelator column (Pharmacia) was used. The agarose beads of the column were thoroughly rinsed with bidest, loaded with 1 column volume of 0.1 M NiSO<sub>4</sub> and immediately rinsed with 5 column volumes of bidest.

##### **Sample preparation:**

The HEK293T supernatant was concentrated, dialyzed to 150 ml PBS(A), supplemented with imidazole to a final concentration of 10 mM and subsequently adjusted to pH 7,5.

##### **Purification:**

The column was equilibrated with 10 volumes of starting buffer (PBS(A) containing 50 mM imidazole, 10% glycerol, pH 8,5) and loaded with the sample using a luer lock syringe. The flow trough was collected.

Ten volumes of starting buffer were used to wash the column and the bispecific Fab-sFb was eluted with PBS(A) containing 400 mM imidazole, pH 8.5.

### Concentration, dialysis and functional analysis of the purified B1Fab-scFv

The eluted fractions were concentrated by ultrafugation (Centricon system, Amicon), diluted in 5 PBS(A) and concentrated again to a final volume of 300  $\mu$ l. Protein concentration was measured with a Biorad DC protein assay (Bio-Rad Laboratories, Hercules, CA, USA) and was determined to be 4 mg/ml. The final amount of purified B1Fab-scFv was 1.3 mg. The purified B1Fab-scFv 10 was used in a T-cell proliferation assay as further described and found to be functional. 1  $\mu$ g of purified BsAb gave rise to a proliferative response comparable as with 1  $\mu$ g non-purified protein (data not shown).

### 15 Flow cytometry

TE<sub>2</sub>, CD3<sup>+</sup> Th-1 cells (Grooten *et al.*, 1989), mouse fibrosarcoma MO4 cells, MO4I4 cells, transfected with the hPLAP gene (Hendrix *et al.*, 1991; kindly provided by Dr. M. De Broe, University of Antwerp, 20 Belgium) and BCL1<sup>vitre</sup> cells (obtained from Dr. K. Thielemans) were used for flow cytometric experiments.

Purified murine monoclonal anti hPLAP antibody E6 (De Waele *et al.*, 1988; Flamez *et al.*, 1995), was used to verify hPLAP expression on the MO<sub>4</sub>I<sub>4</sub> cells. A purified 25 fraction of the parental anti murine CD3 $\epsilon$  145-2C11 monoclonal antibody (Leo *et al.*, 1987, kindly provided by Prof. Dr. J. Plum, RUG, Gent), was used to verify the CD3-expression on TE<sub>2</sub> cells (data not shown).

For indirect immunofluorescence staining, TE<sub>2</sub> cells (CD3<sup>+</sup>) 30 were washed with RPMI1640 medium and resuspended (25 x 10<sup>4</sup> cells per sample) in 500  $\mu$ l of the concentrated and dialysed, BsAb ( $\alpha$ hPLAP x  $\alpha$ CD3) (4  $\mu$ g) and subsequently incubated on ice for 60 min. Likewise, MO<sub>4</sub>I<sub>4</sub> (hPLAP<sup>+</sup>) cells were washed with RPMI medium and 25 x 10<sup>4</sup> cells were 35 incubated with the BsAb ( $\alpha$ hPLAP x  $\alpha$ CD3). After three wash steps with incubation buffer (PBS(A) supplemented with 0.5% BSA and 0.02% NaN<sub>3</sub>), the cells loaded with BsAb were incubated for 60 min on ice in a 1:1000 dilution of

fluorescein-conjugated goat (Fab')<sub>2</sub> fragment to mouse IgG (Fab')<sub>2</sub> (Cappel, West Chester, UK). After a final wash procedure, all cells were resuspended in 300 µl incubation buffer and immediately analysed by flow cytometry, (FACSCalibur; Becton Dickinson, Sunnyvale, CA).

Green fluorescence intensity was measured for the living cell population, which was constantly kept at 4°C. Presentations of the resulting histograms were processed with the WinMDI-software (multiple document interface and Flow cytometry applications, version 2.1.3, TSRI, <http://facs.scripps.edu/software.html>).

Flow cytometric analysis of the bispecific character of BsAb (αBCL1 x αCD3) was essentially performed in a similar procedure, but here different tumor cells and detection systems were used. For immunofluorescence staining of the TE2 (CD3<sup>+</sup>) cells pre-treated with BsAb (αBCL1 x αCD3) (15 µg/ml) we used the biotinylated BCL1 IgM antibody (gift Dr. K. Thielemans) followed by FITC-conjugated streptavidin (Sera-Lab LTD, Crawley Down, U.K.). BCL1<sup>vitro</sup> cells (BCL1<sup>+</sup>) were used to analyse the binding capacity of the chimeric Fab subunit of the bispecific antibody. The cells were loaded with BsAb (αBCL1 x αCD3) and subsequently stained with the following detection antibodies: anti-His tag antibody (Qiagen Inc, Valencia, CA, USA), anti mouse IgG1 (Sigma), anti goat FITC conjugated (Sigma). Finally the green fluorescent cells were counted with a FACSCaliber cytometer.

Flow cytometric analysis of the trispecific (αhPLAP x αBCL1 x αCD3) and the Fab-(scFv)<sub>2</sub> molecule was essentially performed as described above, but different detection antibodies were used: anti mouse IgG γ/κ (1:200 dilution) and chicken anti goat IgG (H+L) FITC (1:200 dilution, Chemicon, Tenecula, CA, USA).

**T-cell proliferation assay**

For the hPLAP tumor model we used MO4I4 tumor cells and splenic T-cells from syngenic C3H/HeOUico, for the BCL1 lymphoma cells we used T-cells from syngenic BALB/c mice. All mice were purchased from the Charles River group (Sulzfeld, Germany) and kept and treated according to guidelines issued from the local ethical commission for animal experiments.

MO4I4 and BCL1<sup>vitro</sup> tumor cells were pre-treated with 50 µg/ml mitomycin C at 37°C in the dark for 12h and 1.5h respectively. After removal of the mitomycin C, 5 x 10<sup>4</sup> tumor cells were co-cultured with the corresponding 1 x 10<sup>5</sup> splenic T-cells in a round bottom well in the presence of the indicated concentration of the BsAb (αhPLAP x αCD3) (αBCL1 x αCD3) or the trispecific molecule (αhPLAP x αCD3 x αBCL1). After 48 h, the cells were pulsed with 0,5 µCi of tritium-thymidine ([<sup>3</sup>H]TdR 1mCi/ml, Amersham). 18 h later the cells were lysed by freezing, the DNA was harvested with an automatic cell harvester and the incorporated radioactivity was measured by scintillation counting using a Top-count machine (Packard, Meriden, CO, USA)

**<sup>51</sup>Cr release assay**

Primary alloreactive CTL responses were generated and investigated with a standard <sup>51</sup>Cr release assay. Briefly, 4 x 10<sup>6</sup> splenic syngenic responder cells (C3H/HeOUico for the hPLAP tumormodel, BALB/c for the BCL1 tumor model) were mixed with 4 x 10<sup>6</sup> splenic allogenic stimulator cells (C57Bl/6) that were treated with 50 µg/ml mitomycin C for 60 min at 37°C in the dark. The mixed cell population was cocultured in 2 ml cultures in complete medium (RPMI 1640, with 10% foetal calf serum, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin, 0.4 mM sodium pyruvate and 5 x 10<sup>-5</sup> M βME) in the presence of 30 U/ml mIL2. These cultures were incubated at 37°C in 5-7% CO<sub>2</sub> in humidified air for 5 days.

Tumor cells (MO4I4 or BCL1<sup>vitro</sup>) were incubated with 150  $\mu$ Ci Na<sup>51</sup>CrO<sub>4</sub> (Amersham, Ghent, Belgium) for 90 min at 37°C and washed carefully (to minimize the spontaneous release). Effector cells from the mixed lymphocyte culture were harvested, washed and 25 x 10<sup>4</sup> cells were plated in triplicate in 96 well U-bottom plates (Falcon, Becton Dickinson, Mountain View, CA, USA) containing 5 x 10<sup>3</sup> tumor cells and bispecific antibody (1  $\mu$ g/ml). The effector/target ratio is 50/1 in a total volume of 200  $\mu$ l. After 4 h incubation at 37°C, 30  $\mu$ l of the culture supernatant was transferred to a luma-plate (Packard, Meriden, CO, USA), air dried and measured with a Top-count machine. The percentage of specific lysis was calculated as 100 x [(experimental release)-(spontaneous release)/(maximum release)-(spontaneous release)]. Maximum release was the value obtained from target cells incubated with 2 % SDS. The spontaneous release never exceeded 14 % of the maximum release.

## 20 Serum stability in vitro

### Serum preparation and sample incubation:

Balb/c mice were treated with an anaesthetic (3.75 mg avertin) and their blood was taken by cardiac puncture. The blood was incubated at 37°C for 60 min, then stored at 4°C for 60 min and subsequently centrifuged at 14 000 rpm for 10 min. The serum was filter sterilised and the Fab-scFv sample was added to a final concentration of 4  $\mu$ g/ml. This was divided in three batches (each 150  $\mu$ l) and incubated at 37°C in sterile conditions. After several periods of time (2 h, 12 h and 24 h), one of the batches was frozen until further analysis.

### 35 Analysis of the remaining activity of Fab-scFv BsAb after serum incubation

The serum stability of the novel Fab-scFv BsAb was investigated using a standard T-cell proliferation assay. We argued that the remaining functional activity



in the serum-incubated samples is correlated to the serum stability of the bispecific protein. The frozen serum samples were submitted in triplicate to a T-cell proliferation assay as described earlier.

5

**EXAMPLE 1****Heterodimerization by CL-CH1 interaction in eukaryotic cells can depend on appropriate VL-VH pairing**

In a first attempt, minibodies were constructed using the CL and CH1 domain on their own to promote heterodimerization of two different scFv molecules. However, after cotransfection of expression plasmids for the VH-VL-CL (scFv-CL) and the VL2-VH2-CH1 (scFv-CH2) fusion proteins, largely all secreted immunoglobulins, detected by an anti mouse IgG  $\gamma/\kappa$  serum were in the monomer format. Inclusion of an E-tag on the C-terminus of the CH1 domain, allowed for the easy discrimination between scFv-CL and the E-tagged scFv-CH1 by immunodetection with an anti E-tag antibody. This clearly showed that the monomers were not scFv-CH1 and that the slight amount of dimers formed did not contain the scFv-CH1 fusion molecule, and hence consisted of scFv-CL molecules alone (data not shown). To avoid possible steric hindrance caused by the fusion of the scFv molecules to the CL and CH1 domains, a derivative was made with a longer flexible linker (16 amino acids: VNHKPSNTKVDKRVEL) separating the fusion partner from CH1. For simplifying the analysis of the construct we used a  $\beta$ -lactamase molecule as a fusion partner, which allows for detection of heterodimers simply on the basis of molecular weight. When co-expressing the bla-CH1 fusion with the scFv-CL fusion, only CL-containing products could be found in the medium with anti mouse IgG  $\gamma/\kappa$  immunodetection. This is especially remarkable since this was also true when the bla-CH1 fusion was co-expressed with a native L chain. L-chains or L-chain derivatives can be expressed on their own and appear as monomers and as homodimers, so they can be secreted without

association to any other partner. The bla-CH1 fusion is not expected to hinder the association of CH1-CL, so it was expected that a L:bla-CH1 dimer should be formed by the interaction of CL and CH1. No product can be seen with the expected molecular weight of the intended heterodimer (Figure 2A). Furthermore, immunodetection with the highly sensitive anti E-tag antibody failed to reveal any trace of a L:bla-CH1 heterodimer (data not shown).

10           However, in the reversed situation when a scFv-CL fusion was co-expressed with a native Fd chain (VH1-CH1), a scFv-CL:scFd heterodimer could be formed (Figure 2B, molecule A3), even when the Fd chain was N-terminally extended with another scFv (scFv-CL:scFv-Fd) (Figure 2B, 15 molecule C1). A more efficient heterodimerization however was observed when the scFv-Fd fusion was co-expressed with the native L chain. This resulted in a bispecific antibody by genetic fusion of a scFv fragment to the N-terminus of the Fd chain of a Fab fragment (Fig 2B, 20 molecule C2), which is a novel format for bispecific antibodies. Due to the fact that the hinge region is not included, both binding specificities remain monovalent.

Both VL-CL:VL-CL (L:L) and VH-CH1:VH-CH1 (Fd:Fd) homodimers could theoretically be formed.

25 Especially L-chain dimer has already been described. The Fd-chain dimer has never been observed, as is also shown in Figure 2C: the complete Fab fragment and L-chain dimer can be expressed, while Fd expression is not detectable in the medium nor in the cellular fraction. This can 30 possibly be due to the described association of endoplasmic chaperones such as BiP with an unpaired Fd chain. When association of the L chain is postponed, the Fd-chain could be degraded instead.

BiP is an endoplasmic (retained in the ER by a KDEL- 35 sequence) chaperone of the HSP70-family that generally binds to exposed hydrophobic patches. The association of BiP with Fd chains or to CH1 domains alone could be responsible for the failure of all scFv-CH1 or BLA-CH1

fusion molecules to pair with an L-chain or a scFv-CL fusion protein. In these molecules, the CH1 domain is not preceded by a VH domain that then could pair with an appropriate VL domain. This could be explained if BiP binds mainly to the CH1 domain, and the displacement could only occur efficiently when also the VH-VL interaction also contributes to the binding energy. If the interaction energies of CH1 with BiP or with CL are at least in the same range, displacement of the chaperone would be inefficient unless the additional free energy of binding, contributed by the interaction of VH with VL, favors displacement. Prolonged unproductive association of BiP with CH1 containing fusion molecules could then lead to targeting the molecules for degradation.

Figure 2 shows that the heterodimerization of CL- and CH1 containing molecules in eukaryotic cells can be dependent on the pairing of appropriate VL and VH domains. The expected molecules after co-expression of CL- and CH1 containing fusion proteins are schematized. Light chain derived domains are in black, heavy chain derived domains are in white, 2CL derived domains are hatched. A Western blot, developed with anti mouse IgG  $\gamma/\kappa$  serum, of a 10% non-reducing SDS-PAGE loaded with supernatant fractions from COS-1 cells, is shown. Beside the pictures of the gels the position of the molecular weight markers (kDa) is shown, as well as the configuration and position of the molecules seen on the gel.

In the figure filled symbols represent all domains from CL-containing molecules; open symbols represent domains from CH1-containing molecules.

A) Co-expression of 2c11scFv-CH1 with E6scFv-CL (molecule A1) or with the natural E6L chain (molecule A2), and of a bla-CH1 fusion (separated by an elongated linker sequence) with E6scFv-CL (molecule B1) or with the natural E6L chain (molecule B2). In lane L1 the E6scFv-CL and in lane L2 the E6L chain alone are loaded. Otherwise, the expected molecule is shown on top of each lane. In

all cases, only the monomeric and dimeric light chain or light chain-derivatives are visible. This was confirmed by developing the same samples with a highly sensitive antibody against the CH1-fused E-tag.

5           B] Lane L1 shows expression of E6scFv-CL alone. Co-expression of E6scFv-CL with an N-terminally extended Fd chain (C1) in stead of an N-terminally extended CH1 molecule (cfr A1 and B1) did result in the formation of an expected heterodimer, although the efficiency of  
10 heterodimerization is low. The heterodimerization efficiency was increased up to more than 90% by co-expressing the scFv-Fd fusion with the natural L chain (C2).

          C] Expression of the Fab chain (Fab) and of the  
15 L chain alone (L) is detectable, but expression of the Fd-chain alone cannot be detected in the medium (med), nor in the cellular fraction (cel).

## 20 **EXAMPLE 2**

### Fab-scFv heterodimers as a model system for bispecific antibodies

One of the disadvantages of using smaller recombinant BsAb molecules such as (scFv)<sub>2</sub> molecules or  
25 dimerized scFv molecules is the relative short reach to far apart antigens. This is especially important if the molecules are intended to link two different cells. When the Fab chains are used as a heterodimerization motif, they can constitute a binding specificity on their own.  
30 To improve upon the interaction range, the second specificity was fused to the other side (C-terminus) of the location of the binding specificity of the Fab fragment. Since a scFv molecule confers the second binding specificity, the molecular weight will still be  
35 low enough to allow rapid tissue penetration, while being high enough to avoid rapid body clearance.

The artificial peptide linker used to connect the scFv to the Fd or the L chain should not contain a

functional hinge region, since this motif can be responsible for a homodimerization of two BsAbs, making them bivalent for each binding specificity. This can be a disadvantage for some applications, since some receptors  
5 can be triggered by crosslinking, leading to premature activation or inactivation of the effector cell. Monovalent binding specificities are for example of great importance when using the molecule to retarget T cells to a tumor site. A bivalent anti-CD3 binding could lead to  
10 systemic CD3 cross-linking, leading to a temporarily T cell activation and a sustained T cell anergy. Also, for some membrane markers, a bivalent binding might induce internalization and removal of the molecule from the cell surface. It is thus important to use the Fab fragment as  
15 a dimerizing unit and not the Fab'. If a functional hinge region is included, it will act as a homodimerization motif on its own, doubling the binding specificities in a substantial part of the expressed molecules, even if two different molecules are expressed together.

20 We have explored the possibility to create monovalent BsAb molecules by fusing a scFv molecule via a linker to the C-terminus of either the Fd or the L chain (Figure 3A). Using this as a model system for the creation of BsAb we were able to obtain very specific  
25 heterodimerization of the L with the Fd-scFv molecules. Up to more than 90% of the secreted immunoglobulin proteins was in the desired bispecific format (Fig. 3A). Furthermore, the L:Fd-scFv format allows efficient production of the BsAb from the culture medium of the  
30 transfected cells. Without amplification, up to 10µg BsAb/ml culture medium could be obtained.

Apparently, the length and composition of the peptide linker connecting the L and the scFv molecules can be varied without any significant drop in the  
35 expression of the L-scFv:Fd heterodimer (Figure 3B). The Fab-scFv fusion protein was expressed as the major immunoglobulin derived product as is shown by immunodetection with anti IgG γ/x and anti E-tag

antibodies. Revelation of the blotted proteins with hPLAP showed the functionality of the Fab fragment. A longer linker could allow a further range of reach for antigen, while a shorter linker, or a different amino acid sequence, might stabilize the fusion product. This could be important when the flexible linker should be vulnerable for proteases present in the environment where the BsAb is expected to function.

As a model for a monovalent BsAb we further characterized the ( $\alpha$ hPLAP)Fab-( $\alpha$ CD3)scFv with the (G4S)<sub>3</sub> peptide linker (H2) for functional binding to cells expressing hPLAP (M<sub>0</sub>01, fibrosarcoma cells) or CD3 (TE2 T cells) on their membrane. The Fab-scFv BsAb ( $\alpha$ hPLAP x  $\alpha$ CD3) was shown to efficiently bind both cells, proving the functionality of both binding sides of this new model for BsAbs (Figure 4A). This binding was not observed with cells that did not express the hPLAP or the CD3 markers (data not shown). To exclude the possibility that fractions of the BsAb bind only one antigen at the same time, we assayed the functionality of the BsAb to bind two cells at the same time. This was done using a T-cell proliferation assay and a T-cell cytotoxicity assay (Figure 4B). These assays clearly showed that indeed the BsAb could bind two different cells at the same time. A clear dose dependent T cell reaction could be seen only when the BsAb with the appropriate specificities ( $\alpha$ hPLAP x  $\alpha$ CD3), and hPLAP expressing cells were used. This clearly proves that the new Fab-scFv model is functional as a bispecific antibody derivative and can redirect CTL activity towards tumor cells.

The Fab part of the molecule can also be a hybrid molecule, where the different domains are derived from different antibodies. Such a chimeric Fab can be constituted from a VH and a VL with a defined specificity, fused to constant domains derived from a different antibody. In figure 5A the expression of a BsAb containing a hybrid Fab fragment with VH and VL domains derived from the B1 anti-BCL1 antibody and constant

domains from the E6 anti-hPLAP antibody is shown to be successfully produced. Again the heterodimerization of the desired bispecific molecule was very selective. The functionality of the binding specificities was shown by  
5 flow cytometry and by functionality in a T-cell proliferation assay and an antibody directed T-cell lysis assay (Figure 5B).

Fusing a second functionality to the Fd chain has the additional advantage that affinity purification  
10 targeted towards the Fd-scFv fusion (e.g. by inclusion of a His-tag in the molecule) removes the remaining non-functional L-chains. As mentioned, Fd:Fd homodimers never occur, so every Fd-chain or Fd-containing fusion protein is paired only with an L-chain or an L-chain derivative  
15 and are therefore in the bispecific format. Due to the efficient heterodimerization of the Fd and the L chain, the main heterologous product formed by transient or stable transformed cell lines is the desired product. Figure 6A shows that the BsAb can be efficiently  
20 expressed in a transiently transformed HEK293T cell line (1µg/ml culture medium) and in a stable transformed SP2/0 defective myeloid cell line (up to 10 µg/ml culture medium). After one-step affinity purification a 70-90% pure BsAb preparation could be obtained, depending  
25 whether the medium contained FCS or not. The purified BsAb was still active in a T-cell proliferation assay (data not shown). Incubation for up to 24h in fresh serum derived from mouse did not result in a significant loss in activity (<30%), again measured by a T-cell  
30 proliferation assay (Figure 6B).

Figure 3 shows the expression of C-terminal Fab-scFv fusion proteins. The model of the BsAb intended by co-expression of two chains is schematically represented. Filled rectangles represent light chain  
35 derived domains, open rectangles heavy chain derived domains. 145-2C11 derived domains are hatched The BsAbs were created by fusing the E6 (αhPLAP) Fab fragment to either the 2c11 (αCD3) or the 3D5 (αHIS) scFv molecules.

Different linker sequences were used to fuse the scFv to the C-terminus of either the L-chain (L2, 4, 5, 6, 7 and 8) or the Fd-chain (H1 and 2), ranging from 4 to 20 amino acids long. The amino acid composition is depicted with a single letter code. The pictures are from protein blots after non-reducing 10% SDS-PAGE of HEK 293T supernatant (harvested 24 h after transfection). The position of molecular weight markers is indicated beside the gel (M).

A] Co-transformation of the L and Fd-scFv expressing vectors result in a high degree of L:L homodimers and relative few Fab-scFv heterodimer (D1). Reversal of the orientation of the scFv (VHVL instead of VLVH) however resulted in more than 90% specific heterodimerization, with few contaminants of unpaired or homodimerized L-chains (D2), while keeping the connecting linker sequence. Essentially the same results were obtained when the interconnecting linker sequence was enlarged to 20 amino acids (D3), or when the scFv was fused to the C-terminus of the L-chain. The blots were probed with goat anti-mouse IgG  $\gamma/\kappa$  serum and revealed with an anti goat alkaline-phosphatase conjugated serum and NBT/BCIP.

B] Expression of a BsAb formed by coupling an anti-His scFv, also in a VLVH format, to the E6 L-chain molecule using five different linker sequences. Immunodetection of the blotted proteins by anti mouse IgG  $\gamma/\kappa$  and anti E-tag shows that all detectable immunoglobulin molecules are in the expected heterodimer format. The first blot was revealed with hPLAP, showing the functionality of the E6 Fab part of the molecule.

In figure 4 it is shown that the C-terminal Fab-scFv fusion proteins are functional as bispecific antibodies.

A] Functional cell binding of the Fab-H2-scFv ( $\alpha$ hPLAP x  $\alpha$ CD3) BsAb was demonstrated by flow cytometry on hPLAP-expressing fibrosarcoma cells (MO4I4) and on CD3 expressing T cells (TE2). The cells were incubated with the secondary detection antibody anti-mouse (Fab')<sub>2</sub>-FITC



(open curves) or pre-treated with the bispecific E6Fab-scFv and subsequently incubated with the detection antibody (filled curves). The bispecific Fab-scFv showed binding both to CD3<sup>+</sup> cells and to hPLAP<sup>+</sup> cells with  
5 satisfactory affinity.

B] Functional cell-cell ligation through the Fab-scFv was demonstrated by T-cell activation upon cross-linking of CD3. The first assay measures T-cell proliferation as a response to the bridging of tumor cells  
10 and spleen cells mediated by the Fab-scFv BsAb ( $\alpha$ hPLAP x  $\alpha$ CD3) protein. For the hPLAP tumor model mitomycin treated M04I4 cells were cocultured with C3H spleen cells (target/responder ratio: 1/20). The non-hPLAP binding Fab-scFv BsAb ( $\alpha$ BCL1 x  $\alpha$ CD3) protein was used as a  
15 control. T-cell proliferation was measured by tritium incorporation and depends on the concentration of the bispecific Fab-scFv.

The second assay measures the killing of the M04I4 target cells by BsAb retargeted cytotoxic T-cells.  
20 A diagram is shown of the cytotoxic response of alloreactive, syngeneic C3H spleen cells upon incubation with <sup>51</sup>Cr labelled M04I4 cells and in the presence of the proper bispecific Fab-scFv. The Fab-scFv BsAb ( $\alpha$ hPLAP x  $\alpha$ CD3) was able to bridge the effector cells to the target  
25 cells (cell ratio 50/1) while the control Fab-scFv ( $\alpha$ BCL1 x  $\alpha$ CD3) BsAb was not. Specific lysis was calculated by dividing the measured lysis minus the spontaneous lysis by the difference between the maximum lysis and the spontaneous lysis. Non-specific lysis was  
30 not over 10% of the maximal lysis.

In both assays, a specific T-cell activation could be noticed that was dependent on the presence of the hPLAP tumor antigen (data not shown), and on the presence and concentration of the Fab-scFv ( $\alpha$ hPLAP x  
35  $\alpha$ CD3) BsAb.

Figure 5 demonstrates that chimeric Fab molecules can be used to construct Fab-scFv bispecific antibodies.

A] Schematic representation of a Fab-scFv BsAb molecule containing chimeric Fab chains. In this example, the VH1 and VL1 domains are derived from the moAb B1, with an anti-BCL1 lymphoma specificity. The hybrid fusion molecule could efficiently be expressed in HEK293T cells as can be seen on the Western blot of a 10% non-reducing SDS-PAGE loaded with supernatant containing the molecules Fab-scFv ( $\alpha$ BCL1 x  $\alpha$ CD3) BsAb (lane 1) or the control molecule bssFv (De Jonge *et al*;, 1995). The detection system used is mentioned underneath each panel. The detected products and the molecular weight markers (kDa) are indicated.

The chimeric Fab-scFv ( $\alpha$ BCL1 x  $\alpha$ CD3) BsAb retained binding specificity as shown by flow cytometry. Histograms are shown of flow cytometry analysis of BCL1<sup>vitro</sup> cells and TE2 CD3<sup>+</sup> T-cells, incubated with the Fab-scFv ( $\alpha$ BCL1 x  $\alpha$ CD3) BsAb and subsequently incubated with the detection antibody (filled curves) or incubated with the detection antibodies alone (open curves). Binding on the BCL1 B-cell lymphoma cells was detected by an anti HIS antibody (Qiagen, DE), followed by incubation with a goat anti mouse IgG1 serum and with a FITC-coupled anti goat serum. Binding to TE2 T-cells was demonstrated by incubation with the biotinylated idiotypic BCL1 IgM moAb followed by incubation with FITC-coupled streptavidin. The Fab-scFv ( $\alpha$ BCL1 x  $\alpha$ CD3) BsAb showed binding to both CD3<sup>+</sup> cells and BCL1<sup>+</sup> cells with satisfactory affinity.

B] The chimeric Fab-scFv ( $\alpha$ BCL1 x  $\alpha$ CD3) BsAb was proven to be active as a BsAb by antibody and target cell dependent activation of T cells, measured by proliferation and specific cytotoxicity assays. The curves show T-cell proliferation as a response to the bridging of lymphoma cells and spleen cells mediated by the Fab-scFv ( $\alpha$ BCL1 x  $\alpha$ CD3) BsAb protein. Mitomycin treated BCL1 cells were cocultured with Balb/c spleen cells in a target/responder ratio of 1/2. T-cell proliferation was measured by tritium incorporation and

decreases with the dilution of the bispecific Fab-scFv. The diagram shows the cytotoxic responses of alloreactive, syngeneic Balb/c spleen cells upon incubation with  $^{51}\text{Cr}$  labelled BCL1<sup>vitro</sup> cells in the presence of the proper bispecific Fab-scFv. The  $\alpha\text{BCL1} \times \alpha\text{CD3}$  Fab-scFv is able to bridge the effector cells to the target cells (effector/target ratio 50/1) while the control BsAb with identical structure but a different specificity ( $\alpha\text{hPLAP} \times \alpha\text{CD3}$ ) was not.

10           Figure 6 illustrates the expression, purification and serum stability of bispecific Fab-scFv molecules ( $\alpha\text{BCL1} \times \alpha\text{CD3}$ ).

          A) Immobilized metal affinity chromatography of bispecific Fab-scFv BsAb ( $\alpha\text{BCL1} \times \alpha\text{CD3}$ ). The culture medium of transiently (HEK293T) or stable (SP2/0) transfected cells was loaded on a NTA- $\text{Ni}^{2+}$  chelating column, eluted with imidazole and analyzed on a non-reducing 10% SDS-PAGE gel and stained with Coomassie Brilliant Blue (CBB). The purified Fab-scFv fractions were loaded in high amounts (10 and 50  $\mu\text{g}$ ) to enable the detection of small contaminating bands. For reference, standard plasma globulin (Sigma) was also loaded in the same quantities. The position of the Fab-scFv BsAb and its molecular weight is indicated. Molecular weight markers (kDa) are indicated on the side of the gel.

          B) Serum stability of a Fab-scFv ( $\alpha\text{BCL1} \times \alpha\text{CD3}$ ). Purified BsAb fractions were incubated for up to 24h in freshly isolated mouse serum. After incubation, the fractions were compared for their biological activity in a T-cell proliferation assay. Balb/c spleen cells were co-cultivated with mitomycin treated BCL1<sup>vitro</sup> cells in the presence of the bispecific B1Fab-scFv incubated in serum for 2, for 12 h or 24 h. Serum without bispecific B1Fab-scFv gave no response. There was no significant loss in activity of the bispecific Fab-scFv after 24 h of serum incubation.

**EXAMPLE 3****Fd:L mediated heterodimerization of two different scFv molecules: efficient expression of trispecific antibodies**

Since C-terminal scFv fusion to either the Fd  
5 or the L chain could be expressed successfully and  
resulted in functional molecules, we investigated whether  
the Fab molecule could still be formed if both chains  
were elongated. When using the L:Fd heterodimerization  
signal to join two scFv molecules, a trispecific molecule  
10 can be created by also using the specificity of the Fab  
molecule created by the L:Fd heterodimerization. This was  
done by co-transfecting a VL-CL-VH2-VL2 (L-scFv) with a  
VH-CH1-VH3-VL3 (Fd-scFv) fusion-protein expressing vector  
(Figure 7A). Especially when fusing two scFv molecules at  
15 the same side of the molecule it is important to monitor  
if binding functionality is not affected by the  
configuration of the TsAb. Fv domains have their antigen  
recognition side more oriented towards the N-terminal  
side, while this is also the side where the fusion to the  
20 Fab chains occur. Since the scFv molecules can be  
expected to direct their binding side more towards the  
Fab fragment, the possibility exists that by the  
'crowding' by both the Fab and the second scFv, the  
binding to an antigen of the first scFv is hindered. From  
25 studies on linkers used in scFv molecules it is known  
that 15 amino acids are necessary to span the diameter of  
a Fv domain. Therefore we assume that such a linker would  
allow the scFv molecule to rotate its binding side away  
from the Fab. Furthermore, two single chain molecules  
30 could be hindering the normal interaction between the  
L:Fd pair and thus inhibit the heterodimerization of the  
TsAb. Therefore we constructed a series of molecules with  
varying peptide linkers connecting the Fab with the scFv  
molecules in two different TsAb models (Figure 7A and  
35 7B). Surprisingly, even the shorter linker sequences (4  
amino acids) allowed efficient heterodimerization, and  
did not inhibit the function of the attached scFv  
molecules (Figure 7 and 8). The TsAb ( $\alpha$ hPLAP x  $\alpha$ BCL1 x

$\alpha$ CD3) with a six amino acid linker connecting the  $\alpha$ BCL1 scFv with the  $\alpha$ hPLAP Fab and with a 20 amino acid linker connecting the  $\alpha$ CD3 scFv with the Fab was further characterized. All binding specificities separately for  
5 cells expressing the appropriate marker could be demonstrated (Figure 8A), as well as the simultaneous binding of one specificity to a (solid) support, while detecting via a second functional group (Figure 8B). In order to show that the molecular design of the TsAb could  
10 allow the molecules to cross-link two antigens that were each fixed on the membranes of a different cell, we measured T-cell activation with a proliferation assay. Since the TsAb contain a binding site for two different tumor markers (hPLAP and BCL1) combined with an  $\alpha$ CD3  
15 specificity, the TsAb should be able to function in a proliferation assay with hPLAP-expressing cells as well as in a proliferation assay using BCL1 expressing cells. Figure 8C shows that this is indeed the case: the TsAb ( $\alpha$ hPLAP x  $\alpha$ BCL1 x  $\alpha$ CD3) combines the activity of two  
20 separate BsAbs ( $\alpha$ hPLAP x  $\alpha$ CD3) and ( $\alpha$ BCL1 x  $\alpha$ CD3), showing a simultaneous activity of the molecular parts along two crucial axes. Clearly, there was no problem of intramolecular crowding that inhibited the  $\alpha$ BCL1 scFv to bind even a lymphoma cell, while also attached to a T-  
25 cell via the second scFv.

This molecule design allows free choice on the position of the binding sites and valence of the end product. A useful molecule with three functional groups could be a bispecific antibody targeting two different  
30 tumor antigens in stead of one (Figure 7 and 8). A bivalent binding to the target cell receptor could be useful if the receptor is only triggered by forming larger aggregates and is insensitive to mere dimerization. In this case, the bivalent binding will  
35 accelerate the formation of aggregates at the target site (Figure 9A). Otherwise, molecules with bivalent or multivalent binding to the target cell while keeping a monovalent binding for the triggering receptor on the

effector cell could be useful to improve on the biodistribution of the antibody derivative (Figure 9B). To improve on binding avidity, it is possible to create multivalent binding antibody derivatives with only one  
5 specificity (Figure 9C). This design could be of importance in order to improve the avidity of molecules to be used for e.g. detection and diagnostics, in vitro as well as in vivo.

The Fd and L chains can also be C-terminally  
10 extended with other molecules than scFv's. The targeting of certain signaling molecules to a predetermined cell type can be useful in therapeutic and diagnostic set up. We show that it is possible to use the L:Fd heterodimerization to associate two IL2 molecules, one  
15 fused to the L chain and another fused to the Fd chain, or to create a trifunctional molecule by fusing a scFv to one chain and a signalling molecule such as IL2 to another (Figure 10).

Figure 7 shows that Fd:L can efficiently  
20 heterodimerize two different scFv molecules.

A] Expression of trispecific antibodies that can target two different tumor antigens. The E6 Fab chains were both extended at their C-terminal side with a scFv molecule. An anti BCL1 tumor marker scFv was fused  
25 to the E6L chain using two different linker sequences: L4 and L5 of 6 and 12 amino acid length respectively. These fusion genes were co-expressed with an E6 Fd - 2c11 scFv (anti CD3 scFv) fusion with an interconnecting linker of 20 amino acids (linker H2). The gels show the medium of  
30 cells expressing the L-scFv alone or in combination with a non-extended Fd chain or with an Fd-scFv fusion. The arrows indicate the position of the L-scFv fusion monomer and dimer, and of the scFv-L:Fd and scFv-L:Fd-scFv heterodimer. All mouse immunoglobulin products were  
35 visualized by probing the blot with goat anti mouse IgG  $\gamma/\kappa$ . The hPLAP developed blot reveals functional hPLAP binding molecules (only E6 L:Fd associations bind hPLAP). The position of the molecular weight markers is indicated

on the side of the gel. Both TsAb molecules were efficiently produced.

B] Influence of linker composition and length on the production of trispecific antibody derivatives. An anti (HIS)<sub>6</sub> scFv carrying an E-tag was coupled to the E6 L chain using five different linker sequences, indicated as L4, L5, L6, L7 and L8. This E-tagged ( $\alpha$ HIS) scFv-L fusion was combined with a HIS-tagged Fd-scFv ( $\alpha$ CD3) and almost exclusively produced scFv-L:Fd-scFv heterodimers as shown by the revelation of the blotted proteins by hPLAP, anti IgG  $\gamma/\kappa$ , anti E-tag and anti HIS-tag. The position of the TsAb and of the molecular weight markers is shown on the side of the gel. All linker combinations gave equal expression levels of the TsAb.

C] In an analogous way, the L-chain with TL8, L4, L5, L6 and L7 linked  $\alpha$ HISscFv could be heterodimerized with the Fd chain with a H1 coupled  $\alpha$ CB3scFv. Especially important is the efficient expression of the L-(L8)-scFv with the Fd-(H1)-scFv, since both linkers are relatively short.

Figure 8 demonstrates the functionality of the trispecific antibody derivatives.

The TsAb ( $\alpha$ hPLAP x  $\alpha$  BCL1 x  $\alpha$ CD3) with the L4 linker was produced to monitor its binding specificities and functionality.

A] All three encoded binding specificities are functional. The TsAb was shown to bind at (1) BCL1 B-cell lymphoma cells (BCL1<sup>+</sup>), (2) MO4I4 fibrosarcoma cells (hPLAP<sup>+</sup>) and (3) to the TE2 T-cell line (CD3<sup>+</sup>). Binding was detected by goat anti mouse serum  $\gamma/\kappa$  followed by an incubation with FITC-coupled anti goat serum.

B] The trispecific antibody derivative is able to bind two different molecules at the same time. While one antigen was fixed on a support (a cell membrane or plastic), a second specificity was used to detect the binding. The TsAb was bound to (1) MO<sub>4</sub>I<sub>4</sub> (hPLAP<sup>+</sup>) cells or (2) to TE2 T-cells, and subsequently incubated with biotinylated BCL1 IgM antibody (BCL1 is an idiotypic

antigen) and FITC-coupled streptavidin. In a third setup BCL1 IgM was coated on MaxiSorb (Nunc) ELISA plates and detected by revealing the bound hPLAP (3). A ( $\alpha$ hPLAP x  $\alpha$ hPLAP x  $\alpha$ CD3) antibody of the same configuration but  
5 lacking the  $\alpha$ BCL1 specificity was used as a negative control. Blanco values were obtained by incubation with the detection antibodies alone (both with FACScan analysis and with ELISA experiments).

C) The trispecific antibody derivatives can  
10 cross-link two different cell markers. The TsAb ( $\alpha$ hPLAP x  $\alpha$ BCL1 x  $\alpha$ CD3) was able to act as efficiently as a BsAb in a T-cell proliferation assay with MO4I4 (hPLAP<sup>+</sup>) cells and in an assay with BCL1 lymphoma cells as targets. This proves that the molecule acts as a bispecific antibody on  
15 both the ( $\alpha$ hPLAP x CD3) and the ( $\alpha$ BCL1 x  $\alpha$ CD3) axes. In this assay, both the TsAb with the L4 and the L5 linkers connecting the  $\alpha$ BCL1 scFv to the L chain were compared.

(1) T-cell proliferation of Balb/c spleen cells upon cocultivation with mitomycin treated BCL1<sup>vitro</sup> cells  
20 in the presence of the trispecific antibody with linker 4 (TsAb (L4)), or with linker 5 TsBab (L5). The linker length between the  $\alpha$ CD3 and  $\alpha$ BCL1 scFv and the Fab as no influence on the bridging capacity of the trispecific antibody.

25 (2) T-cell proliferation of C3H spleen cells upon cocultivation with mitomycin treated MO4I4 cells in the presence of the trispecific antibody with linker 4 TsAb (L4) or with linker 5 TsBab (L5). The control B1Fab-sFb bispecific molecule does not induce T-cell  
30 proliferation. The linker length between the  $\alpha$ BCL1 scFv and the Fab has no influence on the bridging capacity of the two other specificities in the trispecific antibody.

Figure 9 illustrates the expression of multivalent antibody derivatives. Using the model of  
35 extending one or both of the L- or Fd chain of a Fab chain at their C-terminus with scFv molecules can lead to:



A) expression of bivalent T-cell binding bispecific antibody derivatives;

B) expression of bivalent tumor cell binding bispecific antibody derivatives; and

5 C) expression of trivalent tumor cell binding monospecific antibody derivatives. 10% non-reducing SDS gels were blotted and developed with goat anti mouse IgG  $\gamma/\kappa$  followed by alkaline phosphatase coupled anti goat and NBT/BCIP staining, except when indicated that a hPLAP  
10 staining was performed. The FACScan-analysis was performed with the same antibodies, except the last detection antibody was a FITC-coupled anti goat serum. The position of the various antibody forms produced and of the molecular weight markers is shown at the side of  
15 the gels. All derivatives were produced in HEK293T cells by transient co-transformation of vectors expressing the indicated L-chain or Fd-chain fusion proteins. The linker sequences used fuse the scFv to the L or the Fd chain are indicated as L2, L4, L5, L6, L7, H2, H6 and H7 with  
20 single code amino acid sequences. The chains for which the expression vectors were co-transfected are drawn on top of the lanes.

In figure 10 the expression of multifunctional antibody derivatives is shown. The L:Fd interaction can  
25 be used to heterodimerize molecules of different classes. Here, fusion molecules of IL2 with both the L- or the Fd-chain were successfully expressed. This could even be accomplished when using a 3 amino acid linker for fusing to the L chain (L61), combined with a 6 amino acid linker  
30 for fusing to the Fd-chain (H61). The position of the fusion products after non-reducing 10% SDS-PAGE was revealed after protein blotting and immunodetection and is indicated beside the gel, as well as the position of the molecular weight markers run on the gel.

35 Different combinations of native L- and Fd-chains were co-expressed with complementary chains that were extended at their C-terminus with murine IL2 molecules or with a scFv molecule. Native L:Fd chains

were combined (lane 1), as well as L:Fd-(H61)-mIL2 (lane 2), L:Fd-(H62)-mIL2 (lane 3), L-(L61)-mIL2:Fd-(H61)-mIL2 (lane 4), L-(62)-mIL2:Fd-(H62)-mIL2 (lane 5) and L-(L4)- $\alpha$ BCL1scFv:Fd-(L62)-mIL2 (lane 6). The first gel was developed with hPLAP, gels 2 and 3 were developed with goat anti mouse IgG  $\gamma/\kappa$  followed by alkaline phosphatase coupled anti goat and NBT/BCIP staining.

This example shows that also signaling molecules (which can be different or alike) can be dimerized by the L:Fd interaction, without loss of binding activity of the reconstituted Fab fragment. Also molecules belonging to different molecular classes, such as signaling molecules and scFv molecules, can be heterodimerized by the L:Fd interaction.

15

In summary, the present invention relates to a class of molecules specified as novel multipurpose antibody derivatives. This class of molecules is created by heterodimerization of two constituting components. Heterodimerization is obtained by the specific heterotypic interaction of a chosen VH-CH1 combination of immunoglobulin domains, with a chosen VL-CL combination of immunoglobulin domains. The VHCH1-VLCL interaction is proposed as a very efficient heterodimerization scaffold that could be efficiently produced. By choosing the appropriate VH and VL domains in the VHCH1 and VLCL context, a binding specificity can be constituted by the heterodimerization scaffold itself. One or both of the comprising VHCH1 and VLCL chains can thus be extended at either the N- or the C-terminus or both with other molecules, for the purpose of combining these molecules with each other.

The other molecules that are genetically coupled to the heterodimerization scaffold with peptide linkers of choice, can be a toxin polypeptide, an enzyme, a hormone, a cytokine, a signaling molecule, or a single chain linked Fv fragment with the same or a different specificity. In this way, combining three or more

different specificities by combining a Fab molecule with a certain specificity with two or more scFv molecules with two or more different specificities can lead to trispecific or multispecific antibodies derivatives while  
5 maintaining a lower molecular weight.

Also, the method described allows for the production of bispecific antibodies with a bivalent binding of only one specificity, while maintaining a monovalent binding of the other specificity. In its  
10 minimal form, the methods allows for the creation of bispecific antibodies with monovalent binding to each antigen, by combining a specificity encoded by the Fab chains with a single scFv fusion, without the inclusion of a linker sequence derived from an immunoglobulin hinge  
15 region.

This format differs from previously described gene-engineered antibody formats by using the intrinsic behavior of the Fab-chain fragments to heterodimerize. One or more extensions can be made at the N- or C-  
20 terminal side, but never including a hinge region, which by itself is a homodimerizing motif. By not including the hinge region, it is much simpler to obtain monovalent binding specificities in the molecule.

25

#### DEPOSIT DATA

The following deposits were made pursuant to rule 28 EPC:

1. pCAGGSE6L (present in E.coli MC1061 $\lambda$  cells deposited  
30 on October 15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the deposit accession no. LMBP3714)
2. pCA2C11sFvE6Hf (present in E.coli DH5 $\alpha$  cells deposited on October 15, 1997 at the Belgian  
35 Coordinated Collection of Microorganisms and given the deposit accession no. LMBP3715)
3. pCAE6HfGS2C11sFv (also identified as pCAE6H2sc2C11H) (present in E.coli MC1061 cells deposited on October

15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the deposit accession no. LMBP3716)

5

**ABBREVIATIONS**

|    |                   |   |  |
|----|-------------------|---|--|
|    | Ab                | : | antibody   |
|    | $\beta$ ME        | : | $\beta$ -mercaptoethanol   |
|    | BsAb              | : | bispecific antibody  |
| 10 | BssFv             | : | bispecific single chain Fv fragment                                |
|    | BSA               | : | bovine serum albumin   |
|    | BvAb              | : | bivalent antibody  |
|    | C-                | : | carbon-terminus  |
|    | $^{\circ}$ C      | : | degrees Celsius  |
| 15 | 2C11              | : | from 145-2C11 hamster anti CD3 antibody                            |
|    | CD3( $\epsilon$ ) | : | cluster of differentiation 3 ( $\epsilon$ -chain)                  |
|    | CH1, CH3          | : | first and third constant domain of the immunoglobulin heavy chain  |
|    | CL                | : | constant domain of the immunoglobulin light chain                  |
| 20 |                   |   |  |
|    | COS-1             | : | CV-1 cells with defective SV40 origin of replication               |
|    | DNA               | : | desoxyribonucleic acid   |
|    | DMEM              | : | Dulbecco minimal essential medium                                  |
| 25 | EDTA              | : | ethylenediaminetetraacetic acid                                    |
|    | E6                | : | murine monoclonal antibody against hPLAP                           |
|    | <u>E.coli</u>     | : | Escherichia coli   |
|    | f                 | : | fragment   |
|    | Fab               | : | antigen binding fragment including VL, CL, VH and CH1              |
| 30 |                   |   |  |
|    | Fab'              | : | Fab fragment with hinge region                                     |
|    | FACS              | : | Fluorescence activated cell sorter                                 |
|    | Fc                | : | fragment with C-terminal domains of the immunoglobulin heavy chain |
| 35 | FCS               | : | Foetal calf serum  |
|    | Fd                | : | VH-CH1 heavy chain fragment, truncated after CH1                   |
|    | FITC              | : | fluorescein isothiocyanate   |

|          |   |   |
|----------|---|---|
| γ        | : | Ig heavy chain  |
| h        | : | hours   |
| H        | : | Ig heavy chain  |
| HEK      | : | human embryonic kidney cells                              |
| 5 hPLAP  | : | human placental alkaline phosphatase                      |
| Ig       | : | immunoglobulin  |
| IL2      | : | interleukin 2   |
| IMAC     | : | immobilized metal affinity chromatography                 |
| kDa      | : | kilodalton  |
| 10 κ     | : | Ig light chain  |
| l        | : | linker sequence   |
| L        | : | light chain   |
| LB       | : | Luria-Bertani   |
| LMBP     | : | Laboratory of Molecular Biology Plasmid                   |
| 15       | : | Collection  |
| M        | : | molar   |
| min      | : | minutes   |
| mpAb     | : | multipurpose antibody                                     |
| N-       | : | amino-terminus  |
| 20 NP-40 | : | nonidet-P40   |
| PAGE     | : | polyacrylamide gel electrophoresis                        |
| PBS      | : | phosphate buffered saline                                 |
| PCR      | : | polymerase chain reaction                                 |
| rpm      | : | revolution(s) per minute                                  |
| 25 SDS   | : | sodium dodecyl sulfate                                    |
| sec      | : | second  |
| sFv      | : | single-chain linked Fv-fragment                           |
| SV40     | : | simian virus 40   |
| TE       | : | Tris-EDTA-buffer  |
| 30 U     | : | unit  |
| UTR      | : | untranslated region                                       |
| VH, VL   | : | variable domains of the Ig heavy and light chains         |
| 3D5      | : | from the scFv 3D5 specific for (His) <sub>6</sub>         |
| 35 mIL2  | : | mouse interleukin 2                                       |
| Bla      | : | <u>Escherichia coli</u> Beta-lactamase                    |
| H1-7     | : | linker peptide in the heavy chain derived fusion products |

|                     |   |   |
|---------------------|---|---|
| L1-8                | : | linker peptide in the light chain derived fusion products           |
| B1                  | : | hamster mAb against BCL1 idiotype                                   |
| IDA                 | : | International Depositary Authority                                  |
| 5                   | : | LMBP/BCCM Plasmid Collection, K. L. Ledeganckstraat 35, B-9000 Gent |
| CTL                 | : | cytotoxic T-lymphocyte  |
| (Fab') <sub>2</sub> | : | dimerized Fab' fragments  |
| <sup>3</sup> H      | : | tritium   |
| 10 <sup>51</sup> Cr | : | radioactive chromium  |
| α                   | : | anti  |
| CBB                 | : | Coomassie Brilliant Blue  |
| VH2                 | : | VH domain derived from the second antibody                          |
| VL2                 | : | VL domain derived from the second antibody                          |
| 15 VH3              | : | VH domain derived from the third antibody                           |
| VL3                 | : | VL domain derived from the third antibody                           |

**REFERENCES**

- Carter P., Kelley R. F., Rodrigues M. L., Snedecor B., Covarrubias M., Velligan M. D., Wong W. L. T.,  
5 Rowland A. M., Kotts C. E., Carver M. E., Yang M.,  
Bourell J. H., Shepard H. M. and Hennes D. (1992) High  
level *Escherichia coli* expression and production of a  
bivalent humanized antibody fragment. *Bio/Technology* 10,  
163-167.
- 10 Cheung S. C., Dietzschold B., Koprowski H., Notkins  
A. L. and Rando R. F. (1992) A recombinant human Fab  
expressed in *Escherichia coli* neutralizes Rabies virus.  
*J. Virol.* 66(11), 3714-6720.
- Choe, M., Webber K.O. & Pastan I. (1994) - B3(Fab) -  
15 PE38M : a recombinant immunotoxin in which a mutant form  
of *Pseudomonas* exotoxin is fused to the Fab fragment of  
monoclonal antibody B3. *Cancer Res* 54 (13), 3460-3467
- Coloma M. J. and Morrison, S. L. (1997) Design and  
production of novel tetravalent bispecific antibodies.  
20 *Nat. Biotech.* 15, 159-163.
- De Jonge J., Brissinck J., Heirman, C., Demanet C.,  
Leo O., Moser M. and Thielemans K. (1995) Production and  
characterization of bispecific single-chain antibody  
fragments. *Mol. Immunol.* 17(18), 1405-1412.
- 25 De Sutter K., Feys V., Van de Voorde A. and Fiers W.  
(1992a) Production of functionally active murine and  
murine::human chimeric F(ab')<sub>2</sub> fragments in COS-1 cells.  
*Gene* 113, 223-230.
- De Sutter K., Remaut E., & Fiers, W. (1992b)  
30 Disulphide bridge formation in the periplasm of *E. coli*: $\beta$ -  
lactamase: Human IgG3 hinge fusion as a model system.  
*Mol. Microbiol.* 6, 2201-2208.
- De Waele P., Feys V., Van de Voorde A., Molemans F.  
and Fiers W. (1988) Expression in non-lymphoid cells of  
35 mouse recombinant immunoglobulin directed against the  
tumor marker human placental alkaline phosphatase. *Eur.*  
*J. Biochem.* 176, 287-295.

- DuBridge R. B., Tang P., Hsia H. C., Leong P-M., Miller J. H. and Calos M. P. (1987) Analysis of mutations in human cells by using an Epstein-Barr virus shuttle system. *Mol. Cell. Biol.* 7, 379-387.
- 5 Ducancel F., Gillet D., Carrier A., Lajeunesse E., Ménez A. & Boulain J.C. (1993) - Recombinant colorimetric antibodies : construction and characterization of a bifunctional F(ab)<sub>2</sub>/Alkaline Phosphatase conjugate produced in *Escherichia coli*. *Bio/Technology* 11, 601-605
- 10 Flamez D., Remaut E. and Fiers W. (1995) Production in *Escherichia coli* of a functional murine and murine::human F(ab')<sub>2</sub> fragment and mature antibody directed against human placental alkaline phosphatase. *J. Biotechnol.* 42, 133-143.
- 15 Grooten J. and Fiers W. (1989) Acquisition by the murine host of responsiveness towards various neoplastic cell lines, but not towards self, through adoptive transfer of a helper T lymphocyte clone with anti self specificity. *Cancer Res.* 49(14), 3872-3878.
- 20 Hendrix P. G., Dauwe S.E., Van de Voorde A., Nouwen E. J., Hoylaerts M. F. and De Broe M. (1991) Radiolocalisation and imaging of stably hPLAP-transfected MO<sub>4</sub> tumours with monoclonal antibodies and fragments. *Br. J. Cancer* 64, 1060-1068.
- 25 Holliger P., Prospero T. and Winter G. (1993) 'Dibodies': Small bivalent and bispecific antibody fragments. *Proc. Nat. Acad. Sci. USA* 90, 6444-6448.
- Hu S., Shivily L., Raubitschek A., Sherman M., Williams L. E., Wong J. Y. C., Shivily E. J. and Wu A. M.
- 30 (1996) Minibody: A Novel engineered anti carcino-embryonic antigen antibody fragment (single-chain Fv-CH<sub>3</sub>) which exhibits rapid high-level targeting of xenografts. *Cancer Res.* 56, 3055-3061.
- Huylebroeck D., Maertens G., Verhoeyen M., Lopez C.,
- 35 Raeymakers A., Min Jou W. and Fiers W. (1988) High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors. *Gene* 66, 163-181.



- Jost C. R., Kurucz I., Jacobus C. M., Titus J. A., George A. J. T. and Segal D. M. (1994) Mammalian expression and secretion of functional Single-Chain Fv molecules. *J. Biol. Chem.* **269**(42), 26267-26273.
- 5     Knappick, A. & Plückthun, A. (1994) An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments. *Biotechniques* **17**(4), 754-761.
- 10     Laemmli U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.
- 15     Lammerant W., (1994-1995) Produktie van antilichamen, antilichaamderivaten en recombinante immunotoxines in *Saccharomyces cerevisiae*. Rijksuniversiteit Gent, PhD. Thesis.
- 20     Leo O., Foo M., Sachs D. H., Samelson L. E. and Bluestone J. A. (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. *Proc. Natl. Acad. Sci. USA* **84**(5), 1374-1378.
- 25     Mertens, N., Renaut, E. and Fiers, W. (1995) Versatile, multi-featured plasmids for high-level expression of heterologous genes in *Escherichia coli*: overproduction of human and murine cytokines. *Gene* **164**, 1-15.
- 30     Niwa H., Yamamura K. and Miyazaki J. (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* **108**, 193-200.
- 35     Ridgway J. B. B., Presta L. G. and Carter P. (1996) 'Knobs-into-holes' engineering of CH3 domains for heavy chain heterodimerization. *Prot. Eng.* **9**(7), 617-621.
- 40     Smans K. A., Hoylaerts M. F., Narisawa S., Millán J. L. and De Broe M. E. (1995) Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice. *Cancer Res.* **55**, 4383-4390.
- 45     Ward, E.S. Expression and purification of antibody fragments using *E. coli* as a host. (1992). In: Antibody

engineering, a practical guide. Editor: C.A.K.  
Borrebaeck. Publisher: W.H. Freeman and co, New York.

## CLAIMS

1. Multipurpose antibody derivative, comprising the CL and VL domains of a first antibody with a desired first antigen binding specificity, the CH1 and VH domains of the said first antibody interacting with the CL and VL  
5 domains, and one or more other molecules having at least one further purpose coupled to one or more of the domains of the first antibody.

2. Multipurpose antibody derivative as claimed in claim 1, wherein the one or more other molecules are  
10 one or more of the molecules selected from sFv molecules, toxins, enzymes, hormones, cytokines, signalling molecules.

3. Multipurpose antibody derivative as claimed in claim 1, wherein at least two other molecules having  
15 at least one further purpose are coupled to one or more of the domains of the first antibody.

4. Multipurpose antibody derivative as claimed in claim 1, 2 or 3, wherein the coupling of one or more of the domains of the first antibody to the other  
20 molecule(s) takes place via a linker.

5. Multipurpose antibody derivative as claimed in claim 4, wherein the linker is an amino acid chain of at least 1, preferably more than 3 amino acids.

6. Multipurpose antibody derivative as claimed  
25 in claims 1-5, wherein the other molecule(s) is/are coupled to one or more of the following:

the N-terminus of the VH domain of the first antibody,  
the C-terminus of the CH1 domain of the first antibody,  
the N-terminus of the VL domain of the first antibody,  
30 the C-terminus of the CL domain of the first antibody.

7. Multipurpose antibody derivative as claimed in claims 1-6, wherein the first antibody is the E6 antibody directed against human placental alkaline phosphatase (hPLAP) and the sFv consists of the VL and VH  
35 domains of the anti murine CD3 $\epsilon$  antibody 2C11.

8. Multipurpose antibody as claimed in claim 7,  
wherein the VL domain of the 2C11 antibody is at its C-  
terminus fused to the VH domain of the 2C11 antibody via  
a linker and the VH domain of the 2C11 antibody is at its  
5 C-terminus fused to the N-terminus of the VH domain of  
the E6 antibody, which is fused at its C-terminus to the  
N-terminus of the CH1 domain of the E6 antibody.

9. Multipurpose antibody as claimed in claim 8,  
wherein the VH domain of the 2C11 antibody is at its N-  
10 terminus fused to the C-terminus of the VL domain of the  
2C11 antibody via a linker sequence and the VL domain is  
fused at its N-terminus to the C-terminus of the CH1  
domain of the E6 antibody via a linker sequence.

10. Multipurpose antibody as claimed in claim 8,  
15 wherein the VL domain of the 2C11 antibody is at its N-  
terminus fused to the C-terminus of the VH domain of the  
2C11 antibody via a linker sequence and the VH domain is  
fused at its N-terminus to the C-terminus of the CH1  
domain of the E6 antibody via a linker sequence having  
20 the amino acid sequence EPSGP(G<sub>4</sub>S)<sub>4</sub>M.

11. Multipurpose antibody as claimed in claims  
1-10 for use in the treatment of cancer, infections,  
parasites, autoimmune diseases, thrombosis.

12. Multipurpose antibody as claimed in claims  
25 1-10 for use in diagnosis.

13. DNA construct encoding the heavy domain  
containing chains of an antibody as claimed in claims 1-  
10, comprising suitable transcription and translation  
regulatory sequences operably linked to sequences  
30 encoding the VH and CH1 domains of the first antibody and  
optionally a coding sequence for the other molecule  
operably linked thereto.

14. DNA construct as claimed in claim 13,  
wherein the coding sequence for the other molecule  
35 consists of DNA sequences encoding the VL and VH domains  
of a second antibody, which DNA sequences are operably  
linked to each other in either one of the sequences 5'-  
VL2-VH2-3' or 5'-VH2-VL2-3'.

15. DNA construct as claimed in claims 13 and 14, wherein a linker sequence is incorporated between one or more of the VH, CH1, VL2 and/or VH2 coding sequences and/or the coding sequence for the other molecule.

5 16. DNA construct as claimed in claims 13-15, designated as pCA2C11sFvE6Hf and obtainable from E.coli DH5 $\alpha$  cells deposited on October 15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the deposit accession no. LMBP3715.

10 17. DNA construct as claimed in claims 13-15, designated as pCAE6HfGS2C11sFv (also identified as pCAE6H2sc2C11H) and obtainable from E.coli MC1061 cells deposited on October 15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the deposit  
15 accession no. LMBP3716.

18. DNA construct encoding the light domain containing chains of an antibody as claimed in claims 1-10, comprising suitable transcription and translation regulatory sequences operably linked to sequences  
20 encoding the VL and CL domains of the first antibody and optionally a coding sequence for the other molecule operably linked thereto.

19. DNA construct as claimed in claim 18, wherein the coding sequence for the other molecule  
25 consists of DNA sequences encoding the VL and VH domains of a second antibody, which DNA sequences are operably linked to each other in either one of the sequences 5'-VL2-VH2-3' or 5'-VH2-VL2-3'.

20. DNA construct as claimed in claims 18 and  
30 19, wherein a linker sequence is incorporated between one or more of the VL, CL, VL2 and/or VH2 coding sequences and/or the coding sequence of the other molecule.

21. Set of DNA constructs for producing multipurpose antibody derivatives as claimed in claims 1-  
35 10, comprising any one of the constructs claimed in claims 13-17 together with a construct encoding at least the light domains VL and CL of the first antibody.

22. Set of DNA constructs for producing multipurpose antibody derivatives as claimed in claims 1-10, comprising any one of the constructs claimed in claims 18-20 together with a construct encoding at least the heavy domains VH and CH of the first antibody.

23. Set as claimed in claim 21, consisting of vector pCAE6HfGS2C11 and vector pSV51E6L.

24. Set as claimed in claim 21, consisting of vector pCA2C11sFvE6Hf and vector pSV51E6L.

25. Set as claimed in claims 21-24 for use in producing multipurpose antibody derivatives as claimed in claims 1-10 in heterologous expression host cells.

26. Method for producing multipurpose antibody derivatives as claimed in claims 1-10, comprising expression of a set as claimed in claims 21-24 in heterologous expression host cells.

27. Method as claimed in claim 26, wherein the host cells are E.coli cells, other bacterial cells, such as Bacillus spp., Lactobacillus spp. or Lactococcus spp.; actinomycetes; yeasts; filamentous fungi; mammalian cells such as COS-1 cells, HEK cells, insect cells, transgenic animals or plants.

28. Use of multipurpose antibody derivatives as claimed in claims 1-10 for the preparation of a medicament for the treatment of cancer, infections, parasites, autoimmune diseases, thrombosis.

29. Medical preparation comprising multipurpose antibodies as claimed in claims 1-10.

30. Use of multipurpose antibody derivatives as claimed in claims 1-10 for the diagnosis of cancer, infections, parasites, autoimmune diseases, thrombosis.

31. Diagnostic preparation comprising multipurpose antibodies as claimed in claims 1-10.

32. Multipurpose antibody derivative, obtainable by the specific heterotypic interaction of a chosen VHCH1 combination of immunoglobulin domains, with a chosen VLCL combination of immunoglobulin domains, optionally extended at either the N- or the C-terminus or both with

other molecules, such as a toxin polypeptide, an enzyme, a hormone, a cytokine, a signaling molecule, or a single chain linked Fv fragment with the same or a different specificity.

FIGURE 1








FIGURE 2




3/14

FIGURE 3A



4/14

FIGURE 3B



5/14

FIGURE 4A





FIGURE 4B

T-cell proliferation assay:  
tritium thymidin incorporation



CTL mediated, BsAb dependent tumor lysis:  
<sup>51</sup>Cr-release assay




FIGURE 5A




FIGURE 5B




FIGURE 6A






FIGURE 6B




8/14

FIGURE 7A



9/14


FIGURE 7B





10/14



FIGURE 7C





11/14

FIGURE 8



(A)



(B)



(C)



12/14

FIGURE 9A







FIGURE 10



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/00477

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 C07K16/00 C07K19/00 C07K16/46 C12N15/85  
A61K39/395 G01N33/577 //C07K16/28, C07K16/40

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.                     |
|------------|--|---|
| X          | H. HOOGENBOOM: "Mix and match: Building manifold binding sites."<br>NATURE BIOTECHNOLOGY,<br>vol. 15, no. 2, February 1997, pages<br>125-126, XP002084229<br>New York, NY, USA<br>see figure 1, lower-right construct<br>--<br>-/- | 1-6, 11,<br>13-15,<br>18-22,<br>25-29, 32 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"d" document member of the same patent family

Date of the actual completion of the international search

3 June 1999

Date of mailing of the international search report

10/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

## INTERNATIONAL SEARCH REPORT

Intern      nal Application No

PCT/EP 99/00477

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.                                |
|------------|--|--|
| X          | H. FELL ET AL.: "Genetic construction and characterization of a fusion protein consisting of a chieric F(ab') with specificity for carcinomas and human IL-2."<br>THE JOURNAL OF IMMUNOLOGY,<br>vol. 146, no. 7, 1 April 1991, pages 2446-2452, XP002084230<br>Baltimore, MD, USA<br>see abstract<br>see figure 1                    | 1,2,4-6,<br>11,13,<br>18,21,<br>22,<br>25-29,32      |
| X          | F. DUCANCEL ET AL.: "Genetically engineered colorimetric antibody."<br>PROTEIN ENGINEERING,<br>vol. 6, no. suppl., 1993, page 87<br>XP002084231<br>Oxford, GB<br>see the whole document  | 1,2,6,<br>12,13,<br>18,21,<br>22,<br>25-27,<br>30-32 |
| X          | E. NYSSÖNEN ET AL.: "Efficient prouction of antibody fragments by the filamentous fungus <i>Trichoderma reesei</i> ."<br>BIO/TECHNOLOGY,<br>vol. 11, no. 5, May 1993, pages 591-595,<br>XP002084232<br>New York, NY, USA<br>see abstract<br>see figure 1   | 1,2,6,<br>13,18,<br>21,22,<br>25-27,32               |
| X          | M. NEDELMAN ET AL.: "Rapid infarct imaging with a technetium-99m-labeled antimyosin recombinant single-chain Fv: Evaluation in a canine model of acute myocardial infarction."<br>THE JOURNAL OF NUCLEAR MEDICINE,<br>vol. 34, no. 2, February 1993, pages 234-241, XP002084233<br>New York, NY, USA<br>see abstract<br>see figure 5 | 1,2,6,<br>12,30-32                                   |
| X          | D. ANDERSON ET AL.: "Enhanced in vitro tumor cell retention and internalization of antibody derivatized with synthetic peptides."<br>BIOCONJUGATE CHEMISTRY,<br>vol. 4, no. 1, January 1993, pages 10-18,<br>XP002084234<br>Washington, DC, USA<br>see abstract  | 1,2,4-6,<br>11,28,<br>29,32                          |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/00477

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 30 (partially, as far as an in vivo method is concerned) is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.